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D u r in g  W o rld  Wmr I I  F ra n c e  ha d  Rome d i f f i c u l t y  i n  
u s in g  th e  A m e ric a n  p h a rm a c e u t ic a ls  be cause  o f  th e  d i f f e r e n c e  
I n  d o s e s . I t  was th o u g h t  t h a t  th e  c o m p a ris o n  o f  A m e rica n  
and F re n c h  dosea m ig h t  show t h a t  a  r e la t io n s h ip  c o u ld  be 
fo u n d  w h ic h  w o u ld  make I t  e a s ie r  t o  u se  th e s e  f o r e ig n  p ro d u c ts  
I n  F ra n c e .
A s tu d y  o f  o f f i c i a l  d%*uga common to  th e  U n ite d  
S ta te s  P h a rm a co p e ia  X I I I ,  K a t lo n a l  F o rm u la ry  V I I I  and Codex V I ,  
re v e a le d  an  I n t e r e s t i n g  r e l a t i o n s h ip .
S in c e  some p ro d u c ts  s t i l l  k e p t  i n  th e  l a s t  Codex 
h a ve  been  d ro p p e d  b y  th e  U n ite d  S ta te s  P h a rm a co p e ia , I t  was 
n e c e s s a ry  t o  go th ro u g h  a l l  th e  U n ite d  S ta te s  P h a rm n co p e la s ,  
g i v in g  th e  c o r re s p o n d in g  d o s e s , a n d . I n  o r d e r  t o  do t h i s ,  
th e  I n v e s t i g a t o r  fo u n d  I t  n e c e s s a ry  to  go as f a r  b a ck  as th e  
e l ^ t h  r e v i s io n  o f  th e  U n ite d  S ta te s  P h a rm a co p e ia , 1907 .
From t h i s  v a n ta g e  p o in t  I t  was p o s s ib le  to  com pare  th e  p ro ­
g re s s  o f  b o th  dns-'.- ;S s in c e  t h a t  y e a r .  I n  s p i t e  o f  th e  s l i g h t  
v a r i a t io n s  obse v '^ .i, th e  r e l a t i o n  was q u i t e  w e l l  m a in ta in e d .  
T h is  r e l a t i o n  was t r u e  f o r  o n ly  a  p e rc e n ta g e  o f  d m ig s , and 
th e  v a r i a t io n s  fo u n d  w e re  i n  a c c o rd  w i t h  th e  t o x i c i t y  o f  th e  
p r o d u c ts .  A l l  th e  r e la t io n s h ip s  w e re  e s ta b l is h e d  be tw ee n  th e  
U n ite d  S ta te s  P h a n a a co p e la s  aver^^ge dose and th e  Codex V I 
maximum f o r  one d o s e .
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I n  o r d e r  to  com pare F re n c h  and A m e ric a n  maxlmua 
d o s e s , i t  was n e c e s s a ry  to  c o n s id e r  n o n - o f f i c i a l  b u t  com­
m o n ly  u se d  A m e rica n  p h a rm a c e u t ic a l b o o k s . The maximum d o se s  
fo u n d  I n  th e s e  books  com pared fa v o r a b ly  v l t h  th o s e  fo u n d  i n  
Codex T I .
T h e re fo re ,  I n  a g e n e ra l way» i t  ca n  b e  s a id  t h a t  
Codex V I u s e s  th e  A m e ric a n  maximum d o s e , w h i le  th e  U n ite d  
S ta te s  P ha rm aco pe la a  u s e  th e  a v e ra g e  d o s e .
C o n c e rn in g  th e  Codex V I maximum dosea f o r  tw e n ty -  
f o u r  h o u rs ,  w h ic h  c o r re s p o n d  t o  th e  A î^e rlc a n  ca lcu l^ - ’ te d  
d a l l y  d o s e s , a  new r e la t i o n s h ip  was fo u n d  w h ic h  v e r i f i e s  
th e  p r e v io u s  r e s u l t s  i n  t h i s  s tu d y .
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i:-v'TaODUCTîGK
The dose  o f  a  d ru g  t o  be g iv e n  t o  a p a t ie n t  I s
l a r g e ly  a  m a t te r  o f  Judgm en t.
"T h e  U n ite d  S ta te s  P h a rm a co p e ia  a s s ig n s  t o  each 
d ru g  and p r e p a r a t io n  w h a t may be c o n s id e re d  an 
a v e i^ g ©  a d u l t  d o s e , b u t  t h i s  a v e ra g e  dose  m^y be  
in c re a s e d  o r  d e c re a s e d  to  m eet a d e q u a te ly  th e  
e x i s t i n g  c ir c u m s ta n c e s .
"T he  U n ite d  S ta te s  P h a ira a co p e la  and th e  N a t io n a l 
F o rm u la ry  a s s ig n e d  to  each d ru g  and to  m oat 
p r e p a r a t io n s  a n  o f f i c i a l  d o s e . These do ses  a re  
f o r  a d u l t s  and a re  s m a ll enough to  be s a fe  u n d e r  
n e a r ly  a l l  c i r c u m s ta n c e s . " ^
The F re n c h  Codex V I g iv e s  th e  maximum d o s e s . The 
maiin re a s o n  f o r  t h i s  i s  to  g iv e  a l i m i t a t i o n  n o t  f o r  th e  
p h y s ic ia n ,  b u t  f o r  th e  p h a rm a c is t ,  i n  o r d e r  to  re d u c e  h i s  
r e s p o n a l b i l l t y -
A c c o rd in g  to  th e  F re n c h  n a r c o t ic  la w s ,  th e  p h y s i­
c ia n  ha s  t o  s t a t e ,  " I  s a y , "  on  th e  p r e s o r lo t lo n  I f  he  w a n ts  
t o  in c r e a s e  th e  maximum Codex d o s e . W ith o u t  t h i s  n o ta t io n  
th e  p h a rm a c is t  I s  fo r b id d e n  to  f i l l  th e  p r e s c r ip t i o n .
The p h y s ic ia n  has t o  ta k e  i n  c o n s id e r a t io n  th e  
q u a n t i t y  r e a c h in g  an o rg a n ,  and n a t u r a l l y  th e  doee i s  
d e p e n d e n t upon many c o n d i t io n s .  The age ^nd s e x  a re  im p o r­
t a n t  beoAUse o f  d i f f e r e n c e s  i n  w e ig h t ,  i n  f u n c t i o n a l  pecu­
l i a r i t i e s  and I n  c o n s t i t u t i o n a l  r e s is ta n c e .
• U s u a l ly  th e  q u e s t io n  o f  se x  i s  n o t  c o n s id e re d ,  
a l th o u g h  A wowan s h o u ld  t h e o r e t i c a l l y  r e c e iv e  a
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eomewhmt m m a lle r  dome, fro m  o n e - h a l f  t o  f o u r - f i f t h s ,  
n o r  i s  th e  w e ig h t  o f  an a d u l t  deemed o f  s u f f i e l o n t  
p r a c t i c a l  s ig n i f i c a n c e .  The a g e , ho^vever, b e lo w  
tw e n ty  (2 0 )  and above  e l x t y  (GO) i s  a lm o s t  a lw a y s  
c o n s id e re d .
" I n  g e n e ra l I t  may be s ta te d  t h a t  c h i ld r e n  o r  
o ld e r  p e rs o n s  r e q u i r e  le e s  because  o f  d i f f e r e n c e s  
I n  w e ig h t  and B u e c e p t ib l l l t y *
"The  am ount to  be a d m in is te re d  to  c h i ld r e n  I s  
u s u a l ly  c a lc u la t e d  I n  p r o p o r t io n  to  a g e , w e ig h t  o r  
body s u r fa c e ,  m ethods s u f f i c i e n t l y  e x a c t  f o r  
p r a c t i c a l  th e ra p y .
" I t  s h o u ld  be  n o te d ,  h o w e v e r, t h a t  th e  v e r y  yo u ng  
r e q u i r e  even le s s  th a n  th e  c a lc u la te d  am ount and 
a ls o  t h a t  th e s e  m etîiods  do n o t  tf^ke  I n t o  a c c o u n t 
d i f f e r e n c e s  I n  r e a c t i v i t y  to  some d ru g s .
"T h u s  c h i ld r e n  a re  r e l a t i v e l y  t o le r a n t  t o  c a th a r ­
t i c s ,  a t r o p in e ,  a lc o h o l ,  d i g i t a l i s — and v e ry  
s u s c e p t ib le  t o  m o rp h in e .
The am ount f o r  aged p e rs o n s  (a b o u t  60 ) I s  g e n e r a l ly  
f ro m  o n e - h a l f  to  t h r e e - f o u r t h s  o f  t h a t  f o r  o th e r  a d u l t s .
F o r  c h i ld r e n ,  th e  f o l l o w in g  r u le s  a re  em ployed I n  
th e  U n ite d  S ta te s .
C o w lin R *s  B u ie ; M u l t i p l y  th e  ave ra i^e  dose b y  th e  
age a t  n e x t  b i r t h d a y  and  d iv id e  b y  th e  a d u l t  age ( ta k e n  as 
2 4 ) .  T i l ls  i s  th e  m ost com rcn fo r m u la ;  e . g . ,  c h i l d  6 y e a rs  
o ld ,  doee 5
C la r k * a  R u le ; M u l t i p l y  th e  dose b y  th e  w e ig h t o f  
th e  c h i l d  and d iv id e  b y  th e  a v e ra g e  a d u l t  w e ig h t  ( s e le c te d  
AS 150 p o u n d s ) . C le a r ly  t h i s  g iv e s  th e  m ost a c c u ra te  r e s u l t s ;  
e . g . ,  c h i l d  20 p o u n d s , dose  «
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Y oum ;*g  R u le t M u l t i p l y  th e  mge In  y e a rs  by th e  
u re ra g e  d o se  and  d iv id e  b y  th e  age p lu s  1 2 ; e . g . ,  c h i l d  
6 y e a rs  o ld ,  dose  •
F r ie d *8 R u le : ( F o r  I n f a n t s . )  D iv id e  th e  ages
I n  months b y  150 and m u l t i p l y  b y  th e  a v e ra g e  d o s e ; e . g . ,  
c h i l d  6 m on ths  o ld ,  d o se  s
F ra n c e , up  t o  1 9 4 6 , va s  f o l l o w in g  a p p ro x im a te ly  
th e  same r u l e s . ^
Tm^ble o f  O om btng; ( F o r  I n f a n t s . )  U n de r 1 y e a r ,
1 /1 6  t o  l / l 2 f o r  c h i ld r e n  u n d e r  2 y e a rs ,  1 /8
*• 3  •  1 /6
« 4 •* 1 /4
“ 7  •* 1 /3
* 14  "  1 /2
* 20 "  2 /3
fro m  20 t o  60 1
8 ru n to n * e  t.aw l  M u l t i p l y  th e  a d u l t  d o se  b y  th e
age and d iv id e  b y  th e  a d u l t  a g e , ta k e n  as 2 6 ; e . g . ,  c h i l d
6 y e a rs  o ld ,  dose  s   o r
M a r t in e t * s  Law : The c h i l d ' s  dose i s  th e  a v e ra g e
a d u l t  dose  m u l t i p l i e d  b y  num ber o f  y e a rs  p lu s  1 , d iv id e d  b y  
2 0 ;  e . g . ,  c h i l d  8 y e a rs  o ld ,  d o se  •
20
S in c e  th o s e  l a s t  r u le s  d id  n o t  seem t o  be p r e c is e  
enough , th e  S u pp lem e n t o f  Codex 71 w h ic h  a p p e a re d  i n  Novem­
b e r  1 9 4 6 , gave  a t a b le  f o r  c h i l d r e n 's  d o s e s , g i v i n g  th e  
a v e ra g e  d a i l y  dose  f o r  each  d ru g .  On th e  b a s is  o f  th e  r u le s  
f o r  do sag e  uaed i n  th e  U n ite d  S ta te s  and th o s e  used i n  F ra n c e  
i t  i s  p o s s ib le  t o  n o te  th e  e v o lu t io n  i n  dose  le v e l s .
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DISCUSSION
C o m pa ring  th e  p re s e n t  d o se s  to  th e  ones R iv e n  i n  
th e  e % rly  P h e rm n co p e la s  i n  th e  o rd e r* o f  t h e i r  a p p e a ra n c e , 
one can  e a s i l y  see t h e i r  changes and r e s p e c t iv e  p ro g re s s .
S t a r t in g  v l t h  th e  U n ite d  S ta te s  P h a rm aco p e ia  Y I I I #  
19 0 7 , v h lc h  was th e  f i r s t  one  t o  g iv e  a v e ra g e  do ses  and 
w i t h  th e  F re n c h  Codex V , 1 9 2 0 , i t  I s  p o s s ib le  t o  e s t a b l i s h  
a  g ra p h  s h o w in g  t h a t  th e  F re n c h  d o se s  a re  s t i l l  c h a n g in g  
and th e  A m e rica n  domes a re  b e co m in g  s t a b le . *
’? f lth  th e  h e lp  o f  th e  Codex V I l i s t  o f  maximum 
d o s e s ,®  A c o m p a r is o n  ca n  be  e s ta b l is h e d  b e tw e e n  th o s e  doses  
I n  Codex V I  and th o s e  l i s t e d  i n  U n ite d  S ta te s  Pharsnacopela 
X I I I  and l l a t lo n a l  F o rm u la ry  V X I I .  The p r o p o r t io n s  o b ta in e d  
a re  r a t i o s  be tw ee n  th e  o f f i c i a l  A m e ric a n  a v e ra g e  dose  and 
th e  Codex V I  maximum f o r  one d o s e . P r o p o r t io n s  a re  e s ta b ­
l i s h e d  be tw ee n  th o s e  d ru g s  w h ic h  a re  common t o  th e s e  compen­
d ia ;  and to  show th e  r e l a t i o n s h ip  o f t e n  fo u n d  among them , 
a  common f a c t o r  I s  n e ed e d . T h is  f a c t o r  ^111 be  comnon to  
a l l  th e  f o l l o w in g  c a lc u la t io n s .  I t  w i n  be 1 2 0 , and th e  
p r o p o r t io n  1 2 0 /1 2 0  w i l l  be  th e  u n i t .  An A m e rica n  d o se , 
re p re s e n te d  b y  th e  num ber 6 0 , w i l l  be  6 0 / l2 0  o f  th e  F re n c h  
dose  and I t  w i l l  mean, as w e l l ,  o n e - h a l f  o f  th e  F re n c h  d o s e .
*  See, T a b le s  I ,  I I ,  I I I .  F ig u re s  1 ,  2 .
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On t a b le  num ber ÎV ,  a f t e r  th e  H a t  o f  th e  o f f i c i a l  
â o e e a , a  l i s t  o f  t h e i r  r e s p e c t iv e  r a t i o s  I s  show n. T a b le  
num ber V shows th e  r e p a r t i t i o n  o f  th o s e  p r o p o r t io n s .  T h is  
r e p a r t i t i o n  i s  o b ta in e d  b y  p a r t i n g  th e  t o t a l  o f  r a t i o s  i n t o  
g ro u p s  r e le v a n t  t o  th e  u n i t ,  o n e - h a l f  and o n e - fo u r th  o f  th e  
F re n c h  d o s e s , b r in g in g  a lw a y s  th e  new d i v i s i o n  t o  th e  la r g e s t  
g i^ u p .
A p p ro % lm a te ly  f i f t y  p e r  c e n t  o f  th e  U n ite d  S ta te s  
P h a rm a co p e ia  X I I I  and K a t io n a l  F o rm u la ry  V I I I  a v e ra g e  do ses  
v a r y  fro m  o n e - fo u r th  t o  o n e - h a l f  o f  th e  Codex V I  maximum f o r  
one  d o s e . M ore a c c u r a te ly ,  tw e n ty  p e r  c e n t o f  them  f o l l o w  
th e  r a t i o  t h r e e - t e n th s  o f  th e  C odex V I maximum f o r  one dome.
E ln c e  A g r e a t  num ber o f  d ru g s  s t i l l  o f f i c i a l  I n  
Codex V I a re  a le s in g  i n  th e  U n ite d  S ta te s  P h a rm a co p e ia  X I I I  
and N a t io n a l  F o rm u la ry  V I I I ,  many c o m p a ris o n s  have  been 
Im p o s s ib le .  By r e f e r r i n g  to  p r e v io u s  P h a rm a co p e ia s , one 
could f i n d  Almost nil th e  p ro d u c ts  o f f i c i a l  i n  th e  f r e n c h  
Cedex V I .
I n  f o l l o w in g  th e  same p ro c e d u re ,  a  new r e p a r t i t i o n  
o f  r a t i o s  i e  e s ta b l is h e d  on  t a b le  num ber V I I .  Once w ore 
t h r e e - t e n th s  I s  th e  r a t i o  fo u n d  m o s t o f t e n  b e tw e e n  U n ite d  
S ta te s  JPharm acopelas an d  F re n c h  Codex V I d o s e s ; a g a in ,  f i f t y  
p e r  c e n t  o f  th e  A m e ric a n  doses v a r y  fro m  o n e - f o u r t h  to  o n e -  
h a l f  o f  th e  f r e n c h  dome. The o t h e r  f i f t y  p e r  c e n t d i f f e r i n g  
f ro m  th e  g e n e r a l r u l e  may v a r y  p r o p o r t io n a t e ly  to  th e  t o x i c i t y
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o f  th e  d ru g s .  I n  s e p a r a t in g  Codex V I  do ses  by  gram , d e e l -  
g ra a i, c e n t ig ra m  and m i l l ig r a m  d o s e s , n new c o m p a ris o n  csn  , 
be  made w i t h  th e  re e p e c t lT S  A m e rica n  d o s e » .*  Cn f ig u r e  
num ber 3 th e  num ber o f  r a t i o s  t h r e e - t e n th s  a p p e a rs  d e c re a s ­
in g  f ro m  th e  gram  d o se  to  th e  m i l l ig r a m  d o s e . Cn th e  c u r v e ,  
an e x c e p t io n  i s  n o te d ; i n  th e  o r d e r  o f  th e  c e n t ig ra m  d o e e , 
th e  A m e ric a n  doses v a r y  c o n s ta n t ly  fro m  o n e - f o u r t h  to  o n e - 
h a l f  o f  th e  F re n c h  d o s e . I t  I s  i n  th e  o r d e r  o f  th e  c e n t ig ra m  
t h a t  doses  g iv e  m ore o f t e n  th e  g e n e ra l r a t i o  t h r e e - t e n th s :  
and th e  m o s t e i i s i l a r  do ses  ( r a t i o  o f  th e  u n i t )  a re  fo u n d  I n  
th e  o r d e r  o f  th e  m i l l ig r a m .
A l l  th e s e  c a lc u la t io n s  began  w i th  th e  averr^ge 
U n ite d  ro ta te s  P h a rm aco pe ia s  d o s e s . I t  i s  i n t e r e s t i n g  to  
c o n s id e r  now th e  A m e ric a n  maximum do ses  g iv e n  b y  some n o n - 
o f f l c l a l  b u t  com m o n ly -used  A m e ric a n  p h a n s a c c u t le a l b o o k s .
From t h i s  s tu d y  o f  th e  pomology o f  P h a rm a c e u t ic a l T h e ra p e u t ic s ,®  
t r o  r e la t io n s h ip s  a re  e s ta b l is h e d ,  f i r s t  b e tw e e n  A m e rica n  
a v e ra g e  and maximum d o s e s , and s e c o n d ly ,  b e tw ee n  A m e rica n  and 
F re n c h  maximum d o s e s . I t  can  be s ta te d  t h a t  A m e rica n  and 
F re n c h  maximum f o r  one dose  I s  a p p ro x im a te ly  th e  same.
I f  r e  c o n s id e r  th e  l l e t  g iv e n  b y  th e  U n ite d  S ta te s  
D ls p e n e m to ry , ^  th e  a v e ra g e  U n ite d  S ta te s  I'h armaeo p e l as domes 
a re  in t e r r r e d la t e  b e tw e e n  th e  D is p e n s a to ry  m inim um  and maximum
♦  See, T a b le s  V I I J ,  X , X I I ,  X IV .
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d o s e s * The r a t i o s  b e tv e e r i th e  U n ite d  D ta te s  D is p e n s a to ry  
m inim um  and maxlnnim d o se  s t i l l  v a r y  fro m  t h r e e - t e n th s  to  
o n e - h a l f ;  so th e  v a lu e  o f  th e  D la p e n s ^ - to ry  maximums w i l l  
c e r t a i n l y  b e  le g s  th a n  t h a t  g iv e n  b y  P h a rm a c e u t ic a l T h e ra -  
p e u t lc B .  I n  f a c t ,  com pared to  th e  Codex V I maximum f o r  one 
dome In s te a d  o f  va ra r in g  a round  th e  u n i t ,  th e  U n ite d  S ta te s  
D is p e n s a to ry  maximum dome v a r ie s  around, th e  r a t i o  th r e e -  
f i f t h s *  C a lc u la t io n s  show t h a t  th e  a v e ra g e  U n ite d  S ta te s  
P h a rm a co p e ia  do se  le  a b o u t o n e - h a l f  o f  th e  maximum D lm pen- 
e a to ry  d o s e .
A t th e  p r e s e n t ,  o n ly  th e  a v e ra g e  and th e  maximum f o r  
one  dose  ha ve  been c o n s id e re d *  F a c to rs  l i k e  a g e , w e ig h t ,  s e x , 
Id io s y n c r a s y ,  to le r a n c e  and d is e a s e ,  m o d ify  n o t o n ly  th e  s in g le  
do se  o f  A d ru g ,  b u t  a ls o  th e  am ounts w h ic h  can be g iv e n  in  
t w e n t y - f o u r  h o u rs .  The f re q u e n c y  o f  th e  dosage I s  d e te rm in e d  
b y  th e  c o n d i t io n  o f  th e  p a t ie n t ,  o r  I f  c o n t in u e d  e f f e c t  i s  
d e s ir e d ,  b y  th e  r a t e  o f  e l im in a t io n  o f  th e  d ru g .  The Trench 
Codex V I  r e q u i r e s  a maximum dose  f o r  tw e n t y - f o u r  h o u rs ;  so I n  
o r d e r  t o  com pare th e  F re n c h  and A m e rica n  d o s e s . I t  i s  n e c e s s a ry  
t o  c a lc u la t e  th e  A i ie r lc a n  d a i l y  d o ses  fro m  th e  a ve ra g e  d o s e s *
I f  I t  1 b c o n s id e re d  t h a t  th e  a d m in is t r a t io n  o f  th e  a ve ra g e  
dose  o f  m o s t o f  th e  p ro d u c ts  c a n  be  re p e a te d  e v e ry  f o u r  h o u rs ,  
th e  a v e ra g e  A m e rica n  d a l l y  dose  w i l l  be  o b ta in e d  by m u l t i p l y in g  
th e  a v e ra g e  U n ite d  S ta te s  T h a rm a co p e la  dose  b y  s ix -  The c a l ­
c u la t io n s  show t h a t  th e  A m e ric a n  d a i l y  d o ses  c o r re s p o n d  to  th e
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r p t î o  t h r e e - f l f t h a  o f  th e  Codex V I  maximum f o r  t v e n t y - f o u r  
h o u rs .  The Codex V I  maximum f o r  tw e n t y - f o u r  h o u rs  1@ th r e e  
t im e s  t h a t  o f  th e  Codex V I  maximum f o r  one done and te n  t im e s  
la r g e r  th a n  th e  nverap;e U n ite d  S ta te s  P Jia rm acope las d o se .
I n  o r d e r  to  e a t a h l ls h  th e  m ore p r e fe r a b le  a re ra j®  o r  
maximum, A m e ric a n  o r  F ra n c h  d o n e e , I t  I s  I n t e r e s t i n g  to  c o n s i­
d e r  how a n c th e r  c o u n t r y ,  such  as E n g la n d , h a s  o rg a n ix e d  I t®  
dosea and w h a t I s  th e  g e n e ra l Id e a  fo l lo w e d .  The q u e s t io n  i s  
w h e th e r  t h e i r  sys te m s  a re  c lo s e r  t o  th e  A m e rica n  o r  F re n c h  o n e s , 
and w h e th e r . th e y  a re  I n t e r e s te d  i n  an a v e ra g e  o r  a  maximum d o e s . 
A s tu d y  shows t h a t  th e  E n g lle h  P harm acope ia®  g iv e s  tw o d o s e s : 
m inim um  and m a x ia u a . The F re n c h  maximum f o r  one doee i s  gene­
r a l l y  g r e a t e r  th a n  b o th  o f  the m , th e  a v e ra g e  U n ite d  S ta te s  
P harm A cope las  dose i s  g e n e r a l ly  In te r m e d ia te .  So i t  seems much 
e a s ie r  to  e s t a b l i s h  a  r e la t io n s h ip  be tw een  E n g l is h  and A m e ric a n  
do ae e , th a n  b e tw ee n  E n g l is h  and F re n c h  do ses*
I t  I s  d e m o n s tra te d  t h a t  th e  E n g lis h  m inim um  doses  
c o r re s p o n d  t o  one h a l f  o f  th e  U n ite d  S ta te s  Phar^Qacopelas 
a /e ra g e  done  and th e  E n g lis h  maximum, to  t h r e e - f I f t h e  o f  th e  
F re n c h  Codex V I maximum f o r  one d o s e .
I n  v ie w  o f  th e s e  o P e e rv a t io n s , i t  I s  n e c e « fia ry  t h a t  a 
s y s te m a t ic  p r e s e n ta t io n  o f  th e  m a t e r ia l  be made ro  t h a t  r a t i o s  
may be  e s ta b l is h e d  b e tw e e n  F re n c h  and A rn c r ic rn  domes am v v s ll 
AS f o r  A m e ric a n , E n g l le h  and F re n c h  d o se e . I t  I s  V L th  t h i s  
o b je c t  i n  m in d  t h a t  th e  f o l l o w in g  ta P le m  a re  p re s e n te d .
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TABLE I
DOSS VAEIATIONS, U .S .P .  T C F I TO Ü .S .P *  X T H  
F rom  U .S .P ,  S T  t o  O .S .P , x H T
X I
C a rb o n  T e t r a c h lo r id e 1 in c re a s e d t o 2 .5
F rom  U .S .P *  S  t o  U .S .P . w x
Ip e c a c 1 d e c re e s  ed t o 0 .5
M e rc u ro u s  C h lo i ld e 0 .1 5 d e c re a s e d t o 0 .1 2
P a ra ld e h y d e & in c re a s e d t o 4
I o d in e  T in c t u r e 0 .1 in c re a s e d t o 0 .3
F rom  TJ*S*P» ï  t o  IJ»S*P* x T IT
A t r o p in e 0 .0 0 0 6 d e c re a se d t o 0 .0 0 0 4
C a f fe in e 0 .1 5 in c re a s e d t o 0 .2
C h lo r a l  H y d ra te 0 .5 in c re a s e d t o 0 .6
F rom  Ü .S .P .  t 0 Ü .S .P . m i
A c o n ite 0 .0 3 in c re a s e d t o 0 .0 6
A t r o p in e 0 .0 0 0 5 in c re a s e d t o 0 .0 0 0 6
C opper S u l f a t e 0 .2 5 in c re a s e d t o 0 .3
D i g i t a l i s 0 .0 6 in c re a s e d t o 0 .1
E rg o t E r t r a e t 0 .2 5 in c re a s e d t o 0 .5
Hyoscyam us E x t r a c t 0 .0 6 d e c re a s e d t o 0 .0 5
C ro to n  O i l 0 .0 5 in c re a s e d t o 0 .0 6
I o d in e 0 .0 0 5 in c re a s e d t o 0 .0 1
Hyoscyam us 0 .2 5 d e c re a se d t o 0 .2
M e r c u r ic  C h lo r id e 0 .0 0 3 in c re a s e d t o 0 .0 0 4
M e r c u r ic  I o d id e 0 .0 0 3 in c re a s  ed t o 0 .0 0 4
M o rp h in e 0 .0 0 8 in c re a s e d t o 0 .0 1
Nuz V om ica 0 .0 6 in c re a s  ed t o 0 .1
P h o sp h o ru s 0 .0 0 0 5 in c re a s e d t o 0 .0 0 0 6
S c o p o la m in e  E y d ro b ro m id e 0 .0 0 0 3 in c re a s e d t o 0 .0 0 0 5
S o d iu m  A rs e n a te 0 .0 0 5 d e o re a s  ed t o 0 .0 0 3
S o d iu m  H y p o p h o s p h ite 1 d e c re a se d t o 0 .5
S p a r te in e  S u l f a t e 0 .0 1 in c re a s e d t o 0 .0 3
S tra m o n iu m 0 .0 6 in c re a s e d t o 0 .0 7 5
S t r y c h n in e  S u l f a t e 0 .0 0 1 5 in c re a s e d t o 0 .0 0 2
A c o n i te  T in c t u r e 0 .3 in c re a s e d t o 0 .6
B e lla d o n n a  T in c t u r e 0 .7 5 d e c re a se d t o 0 .6
D i g i t a l i s  T in c t u r e 0 .5 in c re a s e d t o 1
N u i V om ica  T in c t u r e 0 .5 in c re a s e d t o 1
Opium T in c t u r e 0 .5 in c re a s e d t o 0 .6
T h m o l 1 in c re a s e d t o 2
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TAEL £  I  (C o n tin u e d  )
F rom  Ü .S .P ,  T O T  t o  U *S .P . Ï Î Î I
Â o e t a n i l i d 0.250 d e c re a s e t o 0.2 _
A c o n i t e 0.065 d e c re a s e t o 0.03 USP
B e lla d o n n a 0.065 d e c re a s e t o 0.06
C o c a in e 0.03 d e c re a s e t o 0.015
C ig i t a i l s 0.065 d e c re a s e t o 0.06 irsp IX
B e lla d o n n a  E x t r a c t 0.01 in c re a s e t o 0.015
C a n n a b is  E x t r a c t 0.01 in c r e a s e  t o 0.015
H yoscyam us E x t r a c t 0.065 d e c re a s e t o 0.06
H y d r a s t in ln e  H y d r o c h lo r id e 0.03 d e c re a s e t o 0.01 _
M e rc u ro u s  C h lo r id e 0.125 in c r e a s e  t o 0.15 USP IX
M o rp h in e 0.01 d e c re a s e t o 0.008 USP IX
M o rp h in e  H y d r o c h lo r id e 0.015 d e c re a s e  t o 0.008
Nuz V om ica 0.065 d e c re a s e  t o 0.06 USP IX
Opium 0.1 dec re a s e t o 0.06
P h e n o l 0.065 d e c re a s e  t o 0.06
P h e n y l S a l i c y l a t e 0.5 d e c re a s e t o 0.3
P i lo c a r p in e  H y d r o c h lo r id e 0.01 d e c re a s e  t o 0.005
P i lo c a r p in e  N i t r a t e 0.01 d e c re a s e t o 0.005
S a n to n in 0.065 dec re a s e t o 0.06
S q u i l l 0.125 d e c re a s e t o 0.1
S o d iu m  N i t r i t e 0.065 d e c re a s e t o 0.06
S tra m o n iu m 0.065 d e c re a s e t o 0.06 USP Tx
S t r y c h n in e 0.001 in c r e a s e t o 0.0015 “
S t r y c h n in e  S u l f a t e 0.001 in c re a s e t o 0.0015 USP 1%
A c o n ite  T in c t u r e 0.6 d e c re a s e t o 0.3 USP Ix
B e lla d o n n a  T in c t u r e 0.5 in c r e a s e  t o 0.75 U3P“fx
C a n th a r ld is  T in c t u r e 0.3 d e c re a s e t o 0.1
C a n n ab is  T in c t u r e 0.6 in c r e a s e t o 0.75
Nuz V om ica T in c t u r e 0.6 d e c re a s e t o 0.5 USP ÎX
T hym o l 0.125 d e c re a s e t o 0.1 US? Ix
C re o s o te 0.2 in c r e a s e  t o 0.25
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TABLE S
DOSE 7A E IA T I0H S , FRENCH CODEX Y TO CODEX VT
'  Pharïoaee u t 1 c a ls
Codex V / ’ 
one do se
maximum 
24 h o u rs
Codex V I ,  maximum 
caie dose 24 h o u rs
A o e t a n i l i d 0 .3 1 .5 d e c re a s e t o 0 .3 1
A c o n ite 1 5 d e c re a s e t o 1 1
A t r o p in e 0 .0 0 0 5 0 .0 0 1 in c re a s e t o 0 .0 0 1 0 .0 0 2
C o de in e 0 .0 5 0 .2 in c r e a s e t o 0 .0 8 0 .3
C o d e in e  fb o s p h a te 0 .0 7 5 0 .3 in c re a s e t o 0 .1 0 .4
C o n in e  H y d ro b ro m id e 0 .0 3 0 .1 5 d e c re a s e t o 0 .0 2 0 .1
M e r c u r ic  C h lo r id e 0 .0 2 0 .0 6 d e c re a s e t o 0 .0 1 5 0 .0 3
M e rc u r ic  I o d id e 0 .0 2 0 .0 8 d e c re a s e t o 0 .0 2 0 .0 4
A n t ip y r in e 4 6 d e c re a s e t o 2 8
P i lo c a r p in e  H y d r o c h lo r id e  0 *0 2 5 0 .0 5 d e c re a s e t o 0 .0 2 0 .0 5
P ip e r a z in e 0 .7 5 3 d e c re a s e t o 0 .6 3
B e s o ro in 1 .2 5 5 d e c re a s e t o 0 .5 3
S od ium  C a c o d y la te 0 .2 0 .2 d e c re a s e t o 0 .1 0 .2
Sodium  C h lo r a te 1 6 d e c re a s e t o 1 4
S o liu m  M e th y la rs e n a te 0 .2 0 .2 d e c re a s e t o 0 .1 0 .2
S p a r te in e  S u l f a t e 0 .0 5 0 .2 5 in c r e a s e t o 0 .1 0 .3
D i g i t a l i s  T in c t u r e 1 .5 5 in c re a s e t o 1 .5 6
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TABLS f l î  
RECAPITÜIATIOK C3F DOSS VARIATIONS 
U n ite d  S ta te s  B ia rz a a c o fe ia a
REVISIONS Hear Va r ia t io n s i^ROPORTION P R O P O K llb i OF \
e 1907 23 \  8 Z ' 8 /3 1  6 2 4 /2 4 1 8 ^ * 2 3 /3 1  1 7 9 4 /2 4 1 8
9 1916 5 21 ^ 2 1 /2 6  1 9 5 3 /2 4 1 8 5 /2 6  4 6 3 /2 4 1 8
10 1926 1 N 2 2 /3  1 6 1 2 /2 4 1 8 1 /3  8 0 6 /2 4 1 8
11 1936 2 2 /4  1 2 0 9 /2 4 1 8 2 /4  1 2 0 9 /2 4 1 8
12 1942 0 \ l  Z' 1 2 4 1 8 /2 4 1 8 0 0
rOTAL 31 ^  54 ^
F re n c h  Oodeoes
EROM S t 06 1920 l g \  5 ^ 5 /1 7  7 2 1 /2 4 1 8 1 2 /1 7  17 0 6 /2 4 1 8
NOTE: in c re a s e s
\  d e c re a s e s
P r o p o r t io n  o f  In c re a s e s  In c lu d e d  i n  r e s p e c t iv e  am ount o f  v a r ia t io n s *  
2418 -  Common f a c t o r  c a lc u la te d  t o  e s t a b l is h  a c u rv e
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N u m e ira fa r  oJ thft TRaHos w h ich  o 
Proportion oi*
%A-\^  j_ C om m o n  D enom 'inatop
Xncreasfcs and JDtcrea^e» _ V a r ia i io i - i  oJ j D g c ra a s a s  
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TABLE l ï  
OFFICIAL DOSE C0MPARI30KS
Ü .S .P .  X I I I . K ,F ,  V I I I . CODEX V I
P h a rm a c e u t ie s ls
Codex ûIsTP. ï ï m  Satib ' iMuiober
Maximum Average Average American In 
one dome dose______dose F re n c h  1 / 1 2 0
A o e t a n i l id
A s p i r in
A c o n ite
Apom orph lne  H y d r o c h lo r id e  
A t ro p in e
A rs e n ic  T r l l o d ld e  
C a f fe in e
C a lc iu m  E y p o p h o s p h lte  
C arbon T e t r a c h lo r id e  
C h lo r a l H y d ra te  
C o ca ine  H y d r o c h lo r id e  
C ode ine
C odeine P h o sp h a te
C o lc h ic in e
C re o so te
A rsphenam lne
D i g i t a l i s
K p h e d rin e  H y d r o c h lo r id e
E s e r in e  S a l i c y l a t e
E th y l M o rp h in e  H y d r o c h lo r id e
B a lla d o n a  E x t r a c t
B a r b i t a l
E rg o t E x t r a c t
E rg o t F lu i d  e x t r a c t
H y d ra s t is  F lu id  e x t r a c t
Ip e c a c  E x t r a c t
Hyoscyamus E x t r a c t
Nux V om ica  E x t r a c t
Opium E x t r a c t
Q u a la c o l
H y d r a s t in ln e  H y d r o c h lo r id e
Ip e c a c
Hyoscyamus
laudanum
M e rc u r ic  I o d id e
M ercu rou s  C h lo r id e
M ercu ro u s  I o d id e
M o rp h in e
M o rp h in e  H y d r o c h lo r id e
0 .3 0 .2 2 /3 SO
1 0 .3 3 /1 0 36
0 .0 5 0 .0 6 6 /5 144
0 .0 1 5 0 .0 0 5 5 /1 5 40
0 .0 0 1 0 .0 0 0 4 4 /1 0 48
0 .0 0 5 ' 0 ,0 0 5 5 /5 120
0 .5 0 .2 2 /5 48
0 .1 0 .5 5 /1 600
2 .5 2 .5 2 5 /2 5 120
4 0 .6 6 /4 0 18
0 .0 5 0 .0 1 5 1 5 /5 0 36
0 .0 8 0 .0 3 3 /8 45
0 .1 0 .0 3 3 /1 0 36
0 .0 0 2 0 .0 0 0 5 5 /2 0 30
0 .5 0 .2 5 2 5 /5 0 60
0 .6 0 .3 3 /5 72
1 0 .1 1 /1 0 12
0 .1 0 .0 2 5 2 5 /1 0 0 30
0 .0 0 1 0 .0 0 2 2 /1 240
0 .0 5 0 .0 1 5 1 5 /5 0 36
0 .0 3 0 .0 1 5 1 5 /3 0 60
0 .5 0 .3 3 /5 72
1 0 .5 5 /1 0 60
1 2 2 /1 240
1 2 2 /1 240
0 .3 0 .5 5 /3 200
0 .1 0 .0 5 5 /1 0 60
0 .0 4 0 .0 1 5 1 5 /4 0 45
0 .1 0 .0 3 3 /1 0 36
0 .5 0 .5 5 /5 120
0 .0 5 0 .0 1 1 /5 24
2 0 .5 5 /2 0 30
0 .2 0 .2 2 /2 120
2 . 0 .6 6 /2 0 36





1 2 /1 0 0
1 /5 24
0 .0 2 0 .0 1 1 /2 60
0 .0 2 0 .0 0 8 8 /2 0 48
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t a b l e  IV  ( c o n t in u e d )
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Codex U .S .P . w .P . R a t io Numb 6]
P h a rm s c e u t lc a ls Maximum A ve ra g e A ve rage A-m erican in
one d o se dose dose .0 re n c h 1 /1 2 0
Opium 0 ,2 0 .0 6 6 /2 0 36
O uaba in 0 .0 0 1 0 .0 0 0 2 5 2 5 /1 0 0 30
P a p a v e r in e  H y d r o c h lo r id e 0 .0 5 0 .1 1 0 /5 240
Paz*aldehyde 5 4 4 /5 96
P h en y l S a l i c y l a t e 1 0 ,3 3 /1 0 36
P h é n o b a rb ita l. 0 .2 0 .0 3 3 /2 0 18
P i lo c a r p in e  H y d r o c h lo r id e 0 .0 2 0 .0 0 5 5 /2 0 30
P i lo c a r p in e  N i t r a t e 0 .0 2 0 .0 0 5 5 /2 0 30
Ip e c a c  end Opium  P ow der 1 0 .3 3 /1 0 36
S a n to n in 0 ,1 0 .0 6 6 /1 0 72
S co p o la m in e  H y d ro b ro m id e 0 .0 0 1 0 .0 0 0 5 5 /1 0 60
Sodium A rs e n a te 0 ,0 1 0 .0 0 3 3 /1 0 36
Sodium C a o o d y la te 0 .1 0 .0 6 6 /1 0 72
Sodium  H y p o p h o s p h ite 0 .1 0 .5 5 /1 600
A rs e n ic  and M e rc u r ic  Io d id e s
1 /5S o l . 0 ,5 0 .1 24
S p a r te in e  S u l f a t e 0 .1 0 .0 3 3 /1 0 36
S tr y c h n in e 0 .0 0 5 0 .0 0 1 5 1 5 /5 0 36
S tr y c h n in e  S u l f a t e 0 .0 0 6 0 .0 0 2 S /6 40
A c o n ite  T in c t u r e 0 *5 0 .6 6 /5 144
C a n th a r ld is  T in c tu r e 0 .5 0 .1 1 /5 24
C o lch icu m  T in c tu r e 1 .5 2 2 0 /1 5 160
Opium T in c tu r e 2 0 .6 6 /2 0 36
D i g i t a l i s  T in c tu r e 1 .5 1 1 0 /1 5 80
Io d in e  T in c t u r e 0 ,3 0 .3 3 /3 120
Hyoscyamus T in c tu r e 1 2 2 /1 240
L o b e lia  T in c tu r e 1 .5 1 1 0 /1 5 80
Nux Vom ica T in c tu r e 1 1 1 /1 120
S tro p h a n tu s  T in c t u r e 0 .5 0 .5 5 /5 120
B e lla d o n n a  T in c t u r e 1 0 .6 6 /1 0 72
Thymol 0 .5 2 2 0 /5 480
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T^BLE V
REPARTITION OF BOSS R̂ .TIOS ESTABLISHED BSIWEKN 
U.S.P, X H T . N.F. VÏÎT. CODEX VI
19
T o ta l > 1 2 0 = 120 < ^20 >60 = 60 <to > 3 0 =  20 < 20
69 12 7 50
50 e 7 35




1 - 5 /3
1 - 4 /3
£ - 6 /5
7 -1 1 - 4 /5
3 - 2 /3
4 - 3 /5
7 - 1 /2 3 - 2 /5
2 - 3 /8
2 -1 /3
1 3 -3 /1 0
6 - 1 /4 5 - 1 /5
2 -3 /2 0
1 -1 /1 0
1 -3 /2 5
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TABIS V I
DOSS COMFAîtISOKS OF FRENCH CODEX V I
AND UNITED STATES ra A R M O P E Ii^S __
INCLUSIVE OF REVISIONS V Î ÎT  TO X Ï Î Î
m
u . a . p .










1 /1 2 0
U .S .P .  x n  Codex S
A r s e n ic  T r io x id e 0 .0 0 2 0 .0 0 5 2 /5 48
P o ta s s iu m  A n tim o n y  T a r t r a t e  0 .0 0 3 0 .1 3 /1 0 0
S od ium  N i t r i t e 0 -0 6 0 .1 6 /1 0 72
P o ta s s iu m  A r s e n i te S o lu t io n  0 .2 0 ,5 2 /5 48
Ü .S .P .  X I  Codex vT
Ammonium S o lu t io n 1 1 1 /1 120
S i l v e r  N i t r a t e 0 .0 1 0 .0 3 1 /3 40
E e lla d o n n a L e a v e s 0 .0 6 0 .1 5 6 /1 5 48
C h lo ro fo rm 0 .3 0 .5 3 /5 72
C o c a in e 0 .0 1 5 0 .0 5 1 5 /5 0 36
C o p p e r S u l f a t e 0 .3 0 .7 5 3 0 /7 5 48
Ami n o p y r in 0 ,3 0 .5 3 /5 72
E rg o t 2 1 2 /1 240
C a n n a b is  E x t r a c t 0 .0 1 5 0 .0 5 1 5 /5 0 36
Io d in e 0 .0 1 0 .0 2 1 /2 60
M e rc u r ic  C h lo r id e 0 .0 0 4 0 .0 1 5 4 /1 5 32
Nux V om ica 0 .1 0 .1 1 /1 120
P h e n o l 0 .0 6 0 .1 6 /1 0 72
A n t ip y r in 0 .3 2 3 /2 0 18
R e s o rc in 0 .1 2 5 0 .5 1 2 5 /5 0 0 30
S tra m o n iu m 0 .0 7 5 0 .2 5 7 5 /2 5 0 36
S q u i l l  T in c tu r e 1 1 .5 1 0 /1 5 80
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Ta BLS V I (C o n t in u e d )
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P h a rm a c e u t ic a ls
U .S .P .





R a t io




1 /1 2 0
Ü ,S .P .  X  Codex W
A c o n i t in e 0 .0 0 0 1 5 0 .0 0 0 2 1 5 /2 0 90
S u lfo n a l 0 .7 5 1 7 5 /1 0 0 90
C o lc h ic u m  E x t r a c t 0 .0 6 0 .0 5 6 /5 144
C u e la c o l C a rb o n a te 1 0 .5 1 0 /5 240
C ro to n  O i l 0 .0 6 0 .0 5 6 /5 144
Io d o fo rm 0 .2 5 0 .2 2 5 /2 0 150
P h o sp h o ru s 0 .0 0 0 6 0 .0 0 1 6 /1 0 72
P o ta s s iu m  C h lo r a te 0 .2 5 1 2 5 /1 0 0 30
S a l i c y l i c  A c id 0 .7 5 1 75 /1 0 0 90
S q u i l l 0 .1 0 .5 1 /5 24
U . S .P . It Codex V I
B ro m o fo rm 0 .2 0 .5 2 /5 48
D ia c e t y l  M o rp h in e 0 .0 0 3 0 .0 1 3 /1 0 36
E th y l  C a rbam ate 1 2 1 /2 60
S q u i l l  F lu i d e x t r a c t 0 .1 0 .2 1 /2 60
Ja b 0 r a n d i 2 5 2 /3 80
B e ta n a p h to l 0 .2 5 1 2 5 /1 0 0 30
C a n n a b is  T in c tu r e 0 .7 5 0 ,5 7 5 /5 0 180
Xf,S .P .  V l i l Codex V I
Conium 0 .2 0 .2 5 2 0 /2 5 96
Coca S 1 2 /1 240
Evonymus 0 .1 2 5 0 .1 1 2 5 /1 0 0 150
H yo scye m in e  a u l f a t e 0 .0 0 0 5 0 ,0 0 0 5 5 /5 120
S a b in a 0 .5 0 .5 5 /5 120
S od ium  C h lo r a te 0 .2 5 1 2 5 /10 0 30
V e r a t r in 0 .0 0 2 0 .0 0 2 2 /2 120
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TABLE 711
BIPARTITIO N OF DOSE RATIOS ESTABLISH EU 
BETWEEN THE UNITED STATES PHARIÆAOOBSIAS 
AND THE FRmCH CODEX H
22
T o ta l >120 ;z l2 0 <120 >60 =60 <60 >30 =  30 <30
144 20 12 82
82 19 10 53




1 - 5 /3
1 - 4 /3
2 - 5 /4  
5 - 6 /5
1 2 -1 2 - 4 /5
3 - 3 /4  
5 - 2 /3
9 - 3 /5
1 0 -1 /2 8 -2 /5
2 - 3 /8
3- 1 /3
1 7 -3 /1 0
1 -4 /1 5
1 0 -1 /4 6 - 1 /5
3 - 3 /2 0
1 -1 /1 0
1 -3 /2 5
1 -3 /1 0 0
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t a b l e vixi
COivJ»AHISON OF DOSES IN IHE ORDER OF THE GBAld




Ü .S .P .
A ve ra g e
d o se
R a t io




1 /1 2 0
A s p i r i n 1 0 .3 3 /1 0 36
Ammonium H y d ro x id e 1 1 1 /1 120
C h lo r a l  H y d ra te 4 0 .5 6 /4 0 18
Coca 1 2 2 /1 240
S u l f o n a l 1 0 .7 5 7 5 /1 0 0 90
D i g i t a l i s 1 0 .1 1 /1 0 12
E rg o t 1 2 2 /1 240
E th y lc a rb a m a te 2 1 1 /2 60
E rg o t  E x t r a c t 1 0 .5 5 /1 0 60
E rg o t  F lu id e x t r a c t 1 2 2 /1 240
H y d r a s t is  F lu id e x t r a c t 1 2 2 /1 240
Ip e c a c 2 0 .5 5 /2 0 30
J a b o ra n d l 3 2 2 /3 80
Laudanum 2 0 .6 6 /2 0 36
M e rc u ro u s  C h lo r id e 1 0 .1 2 1 2 /1 0 0
B e ta n a p h to l 1 0 .2 5 2 5 /1 0 0 30
P a ra ld e h y d e 5 4 4 /5 96
P h e n y l S a l i c y l a t e 1 0 .3 3 /1 0 36
A n t i p y r i n 2 0 .3 3 /2 0 18
P o ta s s iu m  C h lo r a te 1 0 .2 5 2 5 /1 0 0 30
Ip e c a c  and Opium P ow der 1 0 ,3 3 /1 0 36
S a l i c y l i c  A c id 1 0 .7 5 7 5 /1 0 0 90
S od ium  C h lo r a te 1 0 ,2 5 2 5 /1 0 0 30
B e lla d o n n a T in c tu r e 1 0 .6 6 /1 0 72
C o lc h lc u m  T in c t u r e 1 .5 2 2 0 /1 5 160
D i g i t a l i s  T in c tu r e 1 .5 1 1 0 /1 5 8 0
H yoscyam us T in c tu r e 1 2 2 /1 240
L o b e l ia  T in c tu r e 1 .5 1 1 0 /1 5 80
Nux V om ica  T in c tu r e 1 1 1 /1 120
Opium T in c t u r e 2 0 .6 6 /2 0 36
S o u l l l  T in c t u r e 1 .5 1 1 0 /1 5 80
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TABLE IX
REPà ETIT IO K  CfP DOSE RATIOS IK  
TEIE ORDER OF THE OHhM
24
T o ta l >120 =120 < i2 0 >60 =60 <60 >30 = 30 < 3 0
51 6 2 23
23 8 2 13
13 5 ' 4 4
5 -2
1 - 4 /3
2 -1 1 - 4 /5
2 - 3 /4  
4 - 2 /3  
1 - 3 /5
2 - 1 /2 5 -3 /1 0 4—1 /4 2- 3 /2 0
1 -1 /1 0
1- 1 2 /1 0 0
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T à B L l X
COMPAKISON CF DOSES IN  THE ORDER OF 1EE DECIGRAM
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P h a rm a c e u t ic a ls Codex U.S .P . R a t io Number 1 /1 2 0
A e e ta n l l id 0 .3 0 .2 2 /3 80
B e lla d o n n a 0 .1 5 0 .0 6 6 /1 5 40
Brom oform 0 .5 0 .2 2 /5 48
C a ffe in e 0 .5 0 .2 2 /5 48
C a lc ium  H y p o p h o s p h ite 0 .1 0 .5 5 /1 600
C h lo ro fo rm . 0 .5 0 .3 5 /5 72
Conium 0 .2 5 0 .2 2 0 /2 5 96
Codeine P h o sp h a te 0 .1 0 .0 3 3 /1 0 36
C re o so te 0 .5 0 .2 5 2 5 /5 0 60
Copper S u l f a t e 0 .7 5 0 .3 3 0 /7 5 40
Arsphenam ine 0 .6 0 .3 3 /6 60
B a r b i t a l 0 .5 0 .3 3 /5 72
A n in o p y r in 0 .5 0 .3 3 /5 72
E p he d rln e  H y d r o c h lo r id e 0 .1 0 .0 2 5 25 /10 0 30
Euonymus E x t r a c t 0 .1 0 .1 2 5 1 2 5 /1 0 0 150
Ip e ca c  E x t r a c t 0 .3 0 .5 5 /3 200
Hyoscyamus E x t r a c t 0 .1 0 .0 5 5 /1 0 60
Opium E x t r a c t 0 .1 0 .0 3 3 /1 0 36
S q u i l l  E x t r a c t 0 .2 0 .1 1 /2 60
G u e ia co l 0 .5 0 .5 5 /5 120
G u a ia co l C a rb o n a te 0 .5 1 1 /5 24
Io d o fo rm 0 .2 0 .2 5 2 5 /2 0 150
Hyoscyamus 0 .1 0 .1 1 /1 120
Nux Vom ica 0 .1 0 .1 1 /1 120
Opium 0 .2 0 .0 6 6 /2 0 36
Phenol 0 .1 0 .1 1 /1 120
P h é n o b a rb ita l 0 .2 0 .0 3 3 /2 0 18
P o ta ss iu m  A n tim o n y  T a r t r a t e  
R e so rc in
0 .1
0 .5
0 .0 0 3
0 .1 2 5
3 /1 0 0
1 2 5 /5 00 30
Sabina 0 .5 0 .5 5 /5 120
S a n to n in 0 .1 0 .0 6 6 /1 0 72
S q u i l l 0 .5 0 .1 1 /5 24
Sodium N i t r i t e 0 .1 0 .0 6 6 /1 0 72
Sodium C a c o d y la te 0 .1 0 .0 6 6 /1 0 72
Sodium  H y p o p h o s p h ite 0 .1 0 .5 5 /1 600
S o lu t io n  o f  P o ta s s iu m  A r s e n it e 0 .5 0 .2 2 /5 48
A rs e n ic  end M e rc u r ic  Io d id e s  S o l. 0 .5 0 .1 1 /5 24
S p a r te in e  S u l f a t e 0 .1 0 .0 5 3 /1 0 36
S tram onium 0 .2 5 0 .0 7 5 75 /250 36
A c o n ite  T in c tu r e 0 .5 0 .6 6 /5 144
C a n th a r id ia  T in c tu r e 0 .5 0 .1 1 /5 24
C annab is T in c tu r e 0 .5 0 .7 5 7 5 /5 0 180
S tro p h a n tu s  T in c tu r e 0 .5 0 .5 5 /5 120
Thymol. 0 .5 2 2 /5 48
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TABLE x T
REPARTITION OF DOSE RATIOS IN  THE ORDER 
OF THE DECIGRAM
T o ta l )1 E 0 =120 <120 )6 0 =60 <60 )3 0 -3 0 /s o
44 7 6 31
S I 8 4 19
19 11 2 6
2 -5
1 - 5 /3
1 - 3 /2
2 - 5 /4  
1 - 6 /5
6 -1 1 - 4 /5
1 - 2 /3
6 - 3 /5
4 - 1 /2 6 - 2 /5
3 -3 /1 0
i
2 - 1 /4
■
4 - 1 /5
l - S / 2 0
1 -3 /1 0 0
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TABLE X I I
COMPARISON CE DOSES IH  TBE ORDER OF THE CENTIGRAM
P h a rm a c e u ti c a ls Codex U .S .P . R a t io Number 
i n  1 /1 2 0
A c o n ite 0 .0 5 0 .0 6 6 /5 144
S i l v e r  N i t r a t e 0 .0 3 0 .0 1 1 /3 40
C o c a in e , N i t r a t e ,  H y d r o c h lo r id e 0 .0 5 0 .0 1 5 1 5 /5 0 36
C ode ine 0 .0 8 0 .0 3 3 /8 45
D ia c e ty l  M o rp h in e  H y d r o c h lo r id e 0 .0 1 0 .0 0 3 3 /1 0 36
E th y l M o rp h in e  H y d r o c h lo r id e 0 .0 5 0 .0 1 5 1 5 /5 0 36
B e lla d o n n a  E x t r a c t 0 .0 3 0 .0 1 5 1 5 /3 0 60
C annab is  E x t r a c t 0 .0 5 0 .0 1 5 1 5 /5 0 36
C o lc h lc u m  E x t r a c t 0 .0 5 0 .0 6 6 /5 144
Nux Vom ica E x t r a c t 0 .0 4 0 .0 1 5 1 5 /4 0 45
C ro to n  O i l 0 .0 5 0 .0 6 6 /5 144
H y d r a s t in in e  H y d r o c h lo r id e 0 .0 5 0 .0 1 1 /5 24
Io d in e 0 .0 2 0 .0 1 1 /2 60
M e rc u r ic  I o d id e 0 .0 2 0 .0 0 4 4 /2 0 24
M o rp h in e  H y d r o c h lo r id e 0 .0 2 0 .0 0 8 8 /2 0 48
M o rp h in e 0 .0 2 0 .0 1 1 /2 60
P a p a v e r in e  H y d r o c h lo r id e 0 .0 5 0 .1 1 0 /5 240
P i lo c a r p in e ,  N i t r a t e ,  H y d r o c h lo r id e 0 .0 2 0 .0 0 5 5 /2 0 30
Sodium  A rs e n a te 0 .0 1 0 .0 0 3 3 /1 0 36
M e rc u r ic  C h lo r id e 0 .0 1 5 0 ,0 0 4 4 /1 5 32
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
TABLE m i
REPARTITION OF DOSE RATIOS IN  T iiE  ORDER 
OF THE CENTIGRAM
28






10 1 ! 2.
1
1 -2
3 - 6 /5
3 - 1 /2 1 - 2 /5
2 - 3 /8  
1 - 1 /3  
5 -3 /1 0  
1 -4 /1 5
1 - 1 /4 2 - 1 /5
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TABLE X IV
CO&^ARISON OF DOSES IK  THE ORDER OF THE KILLIGHAM
P h a rm a c e u t ic a ls Codex U .S .P . R a t io Number i n  1 /1 2 0
A c o n i t in e 0 .0 0 0 2 0 .0 0 0 1 5 1 5 /2 0 90
A p om orp h ine  H y d r o c h lo r id e 0 .0 1 5 0 .0 0 5 5 /1 5 40
A rs e n ic  T r i i o d id e 0 .0 0 5 0 .0 0 5 5 /5 120
A t r o p in e 0 .0 0 1 0 .0 0 0 4 4 /1 0 48
A rs e n ic  T r io x id e 0 .0 0 5 0 .0 0 2 2 /5 48
C o lc h ic in e 0 .0 0 2 0 .0 0 0 5 5 /2 0 30
E s e r in e  S a l i c y l a t e 0 .0 0 1 0 .0 0 2 2 /1 240
H yo scyem ine  S u l f a t e 0 .0 0 0 5 0 .0 0 0 5 5 /5 120
O u a h a in 0 .0 0 1 0 .0 0 0 2 5 2 5 /1 0 0 30
P h osp ho rus 0 .0 0 1 0 .0 0 0 6 6 /1 0 72
S t r y c h n in e 0 .0 0 5 0 .0 0 1 5 1 5 /5 0 36
S t r y c h n in e  S u l f a t e 0 .0 0 6 0 .0 0 2 2 /6 40
V e r a t r in e 0 .0 0 2 0 .0 0 2 2 /2 120
TABLE XV
REPARTITION OF DOSE RATIOS IN  THE ORDER 
OF THE MILLIGRAM
>120 =120 <120 >60 >50= 60T o ta l =30
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1 - 3 /4
1 - 3 /5
1 -3 /1 0
2 - 1 /3  
2 - 2 /5
1-2 3 -1
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\ Codex R a tio £1 umber R a tio Number
JfcTia rma c eu t  i  0 a l  s Maximum Average Maximum A verage in Maximum in
one dose Maximum 1 /1 2 0 Codex 1 /1 2 0
Opium E x t r a c t 0 .0 6 0 .0 3 0 .1 3 /6 60 6 /1 0 72
G u a ia c o l 0 .6 0 .5 0 .5 5 /6 100 6 /5 144
G u a ia c o l C a rbona te 1 .2 1 0 .5 1 0 /1 2 100 1 2 /5 288
C ro to n  O i l 0 .1 2 0 .0 6 0 .0 5 6 /1 2 60 1 2 /5 288
H y d ra s t in e  E y d ro c h lo r id e 0 .06 0 .0 1 0 .0 5 1 /6 20 6 /5 144
Io d in e 0 .0 3 0 .0 1 0 .0 2 1 /3 40 3 /2 180
Ip e ca c 2 0 .0 6 2 6 /2 0 0 2 /2 120
Hyos cyamus 0 .3 0 .2 0 .2 2 /3 80 3 /2 180
M e rc u r ic  C h lo r id e 0 .0 1 5 0 .0 0 4 0 .0 1 5 4 /1 5 32 1 5 /1 5 120
M e rc u r ic  Io d id e 0 .0 1 5 0 .0 0 4 0 .0 2 4 /1 5 52 15 /20 90
M ercu rous C h lo r id e 0 .6 0 .1 5 1 1 5 /6 0 30 6 /1 0 72
M ercurous Io d id e 0 .0 6 0 .0 1 0 .0 5 1 /6 20 6 /5 144
M o rp h in e  and S a lts 0 .0 3 0 .0 0 8 0 .0 2 8 /3 0 32 3 /2 180
Kux Vomica 0 .2 5 0 .1 0 .1 10 /25 48 25 /10 300
Opium 0 .2 0 .0 6 0 .2 6 /2 0 36 2 /2 120
(Juabain 0 .0006 0 .0 0 0 5 0 .0 0 1 5 /6 100 6 /1 0 72
i'a p a v e r in e  S a lts 0 .5 0 .0 6 0 .0 5 6 /5 0 5 0 /5 1200
P a ra ld e h yd e 5 2 5 2 /5 48 5 /5 120
P heno l 0 .2 0 .0 6 0 .1 6 /2 0 36 2 /1 240
P h e n y l S a l ic y la t e 2 1 1 1 /2 60 2 /1 240
Phosphorus 0 .0 0 2 0.0006 0 .0 0 1 6 /2 0 36 2 /1 240
P i lo c a r p in e  S a lts 0 .0 1 5 0 .0 05 0 .0 2 5 /1 5 40 1 5 /2 0 90















Codex R a tio Number R a tio Number
P h a rm a c e u tic a ls Maximum A verage Maximum A v e ra re in Maximum in
oho dose Maximum 1 /1 2 0 Codex 1 /1 2 0
R e so ro ln 0 ,6 0 .1 2 5 0 .5 125 /6 00 25 6 /5 144
S a n to n in 0 ,3 0 .0 6 0 .1 6 /3 0 24 3 /1 360
S copo lam ine  H y d ro tro m ld e 0.0U06 0 .0 0 0 5 0.001 5 /6 100 6 /1 0 72
Sodium A rs e n a te 0 .006 0 .003 0 .0 1 3 /6 60 6 /1 0 72
Sodium  M  t r i t e 0 .2 0 .0 6 0 .1 6 /2 0 36 2 /1 240
Sodium C a c o d y la te 0 .1 2 0 .0 6 0 .1 6 /1 2 60 12 /10 144
Sodium  H yp o p h o sp h ite 2 0 .5 0 .1 5 /2 0 30 2 0 /1 2400
P o ta ss iu m  A rs e n ite  S o lu t io n 0 .6 0 .2 0 .5 2 /6 40 6 /5 144
S p a r te in e 0 .1 0 .0 3 0 .1 3 /1 0 36 1 /1 120
A c o n it©  T in c tu re 1 0 .6 0 .5 6 /1 0 72 1 0 /5 240
B e lla d o n n a  T in c tu re 2 0 .6 1 6 /2 0 36 2 /1 240
C a n th a r id is  T in c tu re 0 .6 0 .1 0 .5 1 /6 20 6 /5 144
Cannabis T in c tu re 4 1 0 .5 1 /4 30 4 0 /5 960
Io d in e  T in c tu re 0 .3 0 .1 0 .3 1 /3 40 3 /3 120
Hyoscyamus T in c tu re 3 2 1 2 /3 80 3 /1 360
L o b e lia  T in c tu re 2 1 1 /5 1 /2 60 2 0 /1 5 160
Kux Vomica T in c tu re 2 1 1 1 /2 60 2 /1 240
Opium T in c tu re 2 0 .6 2 6 /20 36 2 /2 120
S tro p h a n tu s  T in c tu re 1 0 .5 0 .5 5 /1 0 60 1 0 /5 240
Thym ol 2 0 .1 2 0 .5 12 /200 2 0 /5 480
E th y l M o rp h ine  H y d ro c h lo r id e 0 .0 4 5 0 .0 15 0 .0 5 1 5 /4 5 40 4 5 /5 0 108
B e lla d o n n a  E x t ra c t 0 .0 6 0 ,0 15 0 .0 3 15 /60 30 6 /3 240


















Ta b l e  T 9 T I
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...... 2 6 ___ 8 11
4 - 5 /6
2 - 3 /5
2 - 2 /3
1 9 -1 /2 3 -5 /1 2
3 - 2 /5
8 - 1 /3
9 - 3 /1 0  
3 -4 /1 5
8 - 1 /4 1 -5 /2 4
1 - 1 /5
3 -1 /6
1- 3 /2 0
1- 1 /8
1 -3 /2 5
1 -1 /1 5
1 -3 /5 0
1 -3 /1 0 0
T a b le  tfizf
HEPARTITICN of HATICB w h ic h  CCMPa RE m U M D M  D0G3S 
Ü IV B S  BT *IHASMACKITICAL THSBAPEUTICS'* LYNN 
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1 - 5 /2
2- 1 2 /5
I 2 -2 1 - 5 / i  5...
5- 3 /2
2 - 4 /3  
15- 6 /5  
1 - 1 2 /5
14—1 1- 9/ iO
2 - 3 /4  
6 - 3 /5
2- 1 /2
1- 2 /3






























f ia t io Humber B a tio Humber
P h a rm a c e u tic a ls Codex U .S .P . Minimum Maximum Minimum in Minimum in
U .3 .D . Ü .S .D . Codex 1 /1 2 0 Maximum 1 /120
A e e ta n l l id 0 .3 0 .2 0 .2 0 .7 7 /3 280 2 /7 34
A s p ir in 1 0 .3 0 .3 0 .6 6 /1 0 72 3 /6 60
A o o n lte 0 .0 5 0 .0 6 0 .0 3 0 .0 6 6 /5 144 6 /6 120
Ammonium H y d ro x id e 1 0 .6 2 2 /1 240 6 /2 0 36
Apom orph ine H y d ro c h lo r id e 0 .0 1 5 0 ,005 0 .0 0 4 0 .006 6 /1 5 48 5 /6 100
A rs e n ic  T r i  o x id e 0 .0 0 5 0.0015 0 .0 03 5 /5 72 1 5 /5 0 60
A rs e n ic  T r l io d id e 0 .0 0 5 0 .0 0 5 0 .0 0 3 0 .0 1 2 1 2 /5 288 5 /1 2 50
A tro p in e 0 .0 0 1 0 .0004 0 .0 00 3 0 .0 0 1 2 1 2 /1 0 144 4 /1 2 40
B e lla d o n n a 0 .1 5 0 .0 3 0 .1 2 1 2 /1 5 96 3 /1 2 30
C a ffe in e 0 .5 0 .2 0 .2 3 3 0 /5 720 2 /3 0 8
C a lc iu m  H y p o p h o s p h ite 0 .1 0 .5 0 .5 8 8 0 /1 5 /8 0
16C a n th a r id is 0 .0 3 0 .0 0 4 0 .0 0 3 3 /3 120 4 /3 0
Carhon T e t r a c h lo r id e 2 .5 2 .5 2 .5 40 4 0 0 /2 5 1920 25 /400
C h lo r a l  H y d ra te 4 0 .6 1 2 2 /4 60 6 /2 0 36
C h lo ro fo rm 0 .5 0 .3 1 1 0 /5 240 3 /1 0 36
C oca ine  and S a lts 0 .0 5 0 .015 0 .0 1 5 0 .0 3 3 /5 72 1 5 /3 0 60
C ode ine  H io s p h a te 0 .0 8 0 .0 3 0 .0 3 3 /8 45
C o lc h ic in e 0 .0 0 2 0 .0005 0 .0 005 5 /2 0 30
C re o so te 0 .5 0 .2 5 0 .2 5 1 0 0 /5 0 240
2 5 /8 0D ia m o rp h in e  H y d ro c h lo r id e 0 .0 1 0 .0025 0 .0 0 8 8 /1 0 96
90A rsphenam ine 0 .6 0 .3 0 .2 0 .4 4 /6 80 3 /4
S u lfo n a l 0 ,5 0 .3 0 .3 2 0 ,6 5 6 5 /5 0 156 3 0 /65
E$>hedrlne H y d ro c h lo r id e 0 .1 0 .0 25 0 .0 1 5 0 ,0 5 5 /1 0 60 2 5 /5 0 60
E rg o t 1 1 4 4 /1 480 1 /4 30
E s e rin e  S a l ic y la t e 0 .001 0 .0 0 2 0.O006 0 .0 0 2 2 /1 240 2 /2 120
E th y l M o rp h in e  H y d ro c h lo r id e Ü .05 0 .0 1 5 0 .0 0 8 0 .0 6 6 /5 144 1 5 /6 0 30
B e lla donn a  E x t ra c t 0 .0 3 0 .015 0 .0 1 0 .0 2 2 /5 60 1 5 /2 0 90





























F b s ra ia c e u t lc a ls Codex U .S .P .
B a tio
Minimum Maximum Minimum 
U .S .D . U .S .P . Codex
Number
i n






1 /1 2 0
E rg o t E x t r a c t 1 0 .5 0 .5 5 /1 0 60
I r é c a c  E x t r a c t 0 .3 0 .5 0 .5 2 2 0 /3 800 5 /2 0 30
Eyoseyamus E x t r a c t 0 .1 0 .0 5 0 .0 5 0 .1 3 1 3 /1 0 156 5 /1 3
Nux Vomica E x t r a c t 0 .0 4 0 .015 0 .0 1 5 0 .0 3 3 /4 90 1 5 /3 0 60
Opium E x t r a c t 0 .1 0 .0 3 0 .01 0 .0 6 6 /1 0 72 3 /6 60
I r o n  A rs e n a te 0 .0 5 0 .0 0 6 0 .0 08 8 /5 0 6 /8 90
G u a ia c o l 0 .5 0 .5 0 .3 0 .6 6 /5 144 5 /6 100
C ro to n  O i l 0 .0 5 0 .0 3 0 .1 2 1 2 /5 288 3 /1 2 30
H y d ra s t in in e 0 .0 5 0 .0 1 0 .0 5 0 .1 1 /5 24 1 /1 0 12
Io d in e 0 .0 2 0 .0 0 5 0 .0 6 5 65 /20 390 5 /6 5
Io d o fo rm 0 .2 0 .0 3 0 .2 2 /2 120 3 /2 0 18
Ip e c a c 2 0 .5 1 2 2 /2 120 5 /2 0 30
Hyoscyamus 0 .2 0 .2 0 .1 2 0 .5 3 /2 180 2 /3 60
laudanum E 0 .5 0 .3 0 .6 6 /2 0 36 6 /6 120
M e rc u r ic  C h lo r id e 0 .015 0 .0 01 5 0 .0 08 8 /1 5 64 15 /80
M e rc u r ic  Io d id e 0 .0 2 0 .0 0 4 0 .0 0 3 0 .0 0 5 5 /2 0 30 4 /5 95
M e rc u r ic  C yan ide 0 .0 1 0 .0 0 4 0 .0 1 1 /1 120 4 /1 0 46
M ercurous C h lo r id e 1 0 .1 2 0 .1 2 0 .3 3 /1 0 36 1 2 /3 0 46
M ercurous Io d id e 0 .0 5 0 .0 1 0 .0 1 0 .0 3 3 /5 72 1 /3 40
M o rp h in e 0 .0 2 0 .0 1 0 .0 0 5 0 .0 1 6 16 /20 96 1 0 /1 6 75
M orp h ine  H y d ro c h lo r id e 0 .0 2 0 .0 0 8 0 .0 0 5 0 .0 3 3 /2 80 e/30 32
B e ta n a p h to l 1 0 .1 2 0 .3 3 /1 0 36 1 2 /3 0 48
Opium 0 .2 0 .0 6 0 ,0 3 0 .2 2 /2 120 6/20 36
Ouabain 0 .0 0 1 0 .0 00 25  0 .0 00 25 0 .0 0 0 5 5 /1 0 60 2 5 /5 0 60
P a p a v e rin e  H y d ro c h lo r id e 0 .0 5 0 .1 0 .0 6 0 .2 2 /5 48 1 /2 60
P a ra ld e h yd e 5 4 2 6 6 /5 144 4 /6 60
P e l le t i e r in e 0 .4 0 .2 0 .3 3 /4 90 2 /3 80
P h e n y l S a l ic y la t e 1 0 .3 0 .3 1 1 /1 180 3 /1 0 36
P h é n o b a rb ita l 0 .2 0 .0 3 0 .0 1 5 0 .1 2 1 2 /2 0 72 3 /1 2 30
































R a tio Number R a tio Number
P h a rm a c e u tic a ls Codex Ü .S .P . Minimum Maximum Maximum i n Minimum in
U .S .D . U .S .D . Codex 1 /1 2 0 iiaxlmum 1 /1 2 0
Phosphorus 0*001 • 0 .0005 0 .0 0 2 2 /1 840 5 /20 30
P i lo c a r p in e  H y d ro c h lo r id e 0 .0 2 0 .005 0 .0 0 3 0 .0 06 6 /2 0 36 5 /6 100
P ip e ra z in e 0 .3 0 .3 0 .6 6 /3 240 3 /6 60
P o ta ss iu m  A n tim ony  T a r t r a te 0 .1 0 .0 0 1 5 0 .0 0 8 8 /1 0 0 15 /80
Ip e c a c  end Opium Powder 1 0 .3 0 .2 0 .6 6 /1 0 72 3 /6 60
Ruta 0 .5 0 .6 2 2 0 /5 480 6 /2 0 36
S a n to n in 0 .1 0 .0 6 0 .0 6 0 .2 2 /1 240 6 /2 0 36
S copo lam ine  H yd rob rom id e 0 .0 0 1 0 .0 0 0 5 0 .0 0 0 5 0 .0 0 1 1 /1 120 5 /1 0 60
Sodium  N i t r i t e 0 .1 0 .0 6 6 /1 0 72
3 /10Sodium  C h lo ra te 1 0 .3 1 1 /1 120 36
Sodium M e th y la rs e n a te 0 ,1 0 .0 2 0 .0 6 6 /1 0 72 2 /6 40
T r i n i t r l n  S o lu t io n 0 .1 0 .0 6 6 /1 0 72
3 /1 2S p a r te in e  S u lfa te 0 .1 0 .0 3 0 .0 1 0 .1 2 1 2 /10 144 30
S try c h n in e 0 .0 05 0 .0 0 1 5 0 .0 0 1 0 ,0 04 4 /5 96 1 5 /4 0 45
S try c h n in e  S u lfa te 0.006 0 .0 0 2 0 .0 0 1 0 .004 4 /6 80 2 /4 60
S tram onium 0.2 5 0 .0 6 0 .2 20 /25 96 6 /2 0 36
A c o n ite  T in c tu re 0 .5 0 .6 0 .3 1 1 0 /5 240 6 /1 0 72
B e lla d o n n a  T in c tu re 1 0 .6 0 .3 1 1 /1 120 6 /1 0 72
C a n th a r id is  T in c tu re 0 .5 0 .1 0 .0 6 0 .8 2 /5 48 1 /2 60
C o lch lcum  T in c tu re 1 .5 2 0 .6 2 2 0 /1 5 160 2 /2 120
D i g i t a l i s  T in c tu re 1 .5 1 0 .3 2 2 0 /1 5 160 1 /2 60
Io d in e  T in c tu re 0 .3 0 .3 0 .0 6 0 .3 3 /3 120 3 /3 120
Hyoscyamus T in c tu re 1 2 2 4 4 /1 480 2 /4 60
L o b e lia  T in c tu re 1 .5 1 0 .6 2 2 0 /1 5 160 1 /2 60
Nux Vomica T in c tu re 1 1 0 .6 2 2 /1 240 1 /2 60
Opium T in c tu re 2 0 .6 0 .3 0 .6 6 /2 0 36 6 /6 120
S q u i l l  T in c tu re 1 .5 0 .3 2 20 /15 160 3 /2 0 IB
S tro p h a n tu s  T in c tu re 0 .5 0 .5 0 .2 0 .5 5 /5 120 5 /5 120
Y o h im b in e  H y d ro c h lo r id e 0 ,0 1 0 .0 0 5 5 /1 0 60
Z in c  P h osph id e 0 ,0 0 8 0 .0 0 3 3 /8 45
38
TABLE ^
REPARTITION OF m T IO S  WHICH COMPARE MINIMUM AND 
MAXIMUM DOSES GIVEN BT THE *Ü ÎÏITED STATES DISPBNSa T ü EY
2 4 th  EDITION







"7 = 1 3 - 5 /6
1 - 4 /5
3 -3 /4
3 - 2 /3
1 - 5 /8
2 - 3 /5
1 7 -1 7 2 1—6 / l3 f  9—1 /4
1 -5 /1 2 !
2 - 2 /5  i 
l - S /1 3 !
1 - 3 /6  1
1 0 -3 /1 0
1 -2 /7
1-4 /151
3 - 1 /3
.............  i
1 -1 6 /6 5
2 -3 /2 0
2 -3 /1 5  
1 -1 /1 0  
1 -1 /1 3
3 -1 /1 6  
1 -2 /1 5  
1 -1 /1 5
TABLE S '
REPARUTION QP RATIOS WHICH COüPARE ^UNITED STATES 
DISPENSATORY 24 •♦MAXIMUM DOSES AND FRENCH CODEX V I
MAXIMUM FOR ONE DOSE





' ........ ............ .
}
14 ; 11 33
. . . . . .  j




1 -2 0 /2
1—6
3—4
1 - 1 3 /4
2 - 1 2 /5  
1 - 7 /3
9-2
!
1 - 3 /2  i l l - 1  
4 - 4 /3  
3 -1 3 /1 0  





5 - 4 /5  6 - 1 /2  
2- 3 /4  
4 - 2 /3  
10- 3 /5  :




5 - 3 /1 0
2 - 1 /4
1 - 1 /5
1- 4 /2 5
1 -2 /2 5
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
TABLE lÔ g T
CaiPARlSON GP ÂMEHICAN DAILY DOS IB  a HD FEm cE  
CODEX V I. MAXIMUM D C S ^ FOR T^ENTY-FOUR HCÜS3
C a lc u la te d Codex jâ a t io Number
P h a rm a c e u tic a ls A m e rica n Maximum d a i l y i n
d a l l y  dose f o r  24 h o u rs  Maximum 1 /1 2 0
A e e ta n l l id  (0 * 2 ) 6 -1 .2 1 1 2 /1 0 144
A s p ir in  ( 0 . 3 ) 6 -1 .8 6 1 8 /6 0 36
A c o n ite  (0 .0 6  j 6 -0 .3 6 0 .1 5 3 6 /1 5 288
Apom orphine ( 0 .0 0 5 ) 6 -0 .0 3 0 .0 1 5 3 0 /1 5 240
A rs e n ic  T r ic n c ld e  (0 .0 0 5 ) 6 -0 .0 3 0 .0 15 3 0 /1 5 240
A tro p in e  (0 .0 0 0 4 )6 -0 .0 0 2 4  0 .0 0 a 2 4 /2 0 144
C a ffe in e  ( 0 .2 ) 6 -1 ^2 2 1 2 /2 0 72
C a lc ium  H y p o p h o s p h ite  ( 0 ,5 ) 6 -3 0 .5 3 0 /5 720
Carbon T e t r a c h lo r id e  ( 2 . 5 ) 6—15 ■ 2 .5 15 0 /25 720
C h lo ra l H y d ra te  ( 0 . 6 ) 6 - 3 . ^ 12 3 6 /1 2 0 36
C ocaine (0 .0 1 5 ) 6 -0 .0 9 o;i5 9 /1 5 72
Codeine [0 .0 3 ) 6 -0 .1 8 0 .3 1 8 /3 0 72
Codeine P h osp ha te 0 .0 3 ) 6 -0 .1 8 0 .4 1 8 /4 0 54
C o lc h ic in e ;0 .0005 6 -0 .0 0 3 0 .0 0 4 3 /4 90
C reoso te 0 .2 5 ) 6 -1 .5 1 .5 1 5 /1 5 120
Arsphenam ine [0 .3 ) 6 -1 ,8 0 .6 1 8 /6 360
S u lfo n a l. 0 .3 ) 6 - 1 .8 1 1 8 /1 0 216
D ig i t a l i s 0 .1 ) 6—0 .6 1 6 /1 0 72
E phedrlne  H y d ro c h lo r id e 0 .0 2 5 ) 6 -0 .1 5 0 .3 1 5 /3 0 60
E se rine ;0 .0 0 2 ) 6 -0 .0 1 2 0 .0 0 3 1 2 /3 480
% h y l M o rp h in e  H y d ro c h lo r id e 0 .0 1 5 } 6 -0 .0 9 0 .2 9 /2 0 54
B e lladonna la c tra c t [0 .0 1 5 ) 6 -0 ,0 9 0 .1 9 /1 0 108
E rgo t E x t r a c t 0 .5 ) 6 -3 5 3 /5 72
E rgot F lu id e x t r a c t 2 ) 6 -1 2 5 1 2 /5 288
H y d ra s t is  E x t r a c t [2 ) 6 -1 2 4 1 2 /4 480
Ipecac E x t r a c t 1 0 .5 ) 6 -3 0 .3 3 0 /3 12
Hyoscyamus E x t r a c t 0 .0 5 ) 6 - 0 .3 0 .3 3 /3 120
Kux Vomica E x t r a c t 0 .0 1 5 ) 6 -0 .0 9 0 .1 9 /1 0 108
Opium E x t r a c t :0 .0 3 ) 6 -0 .1 8 0 .3 1 8 /3 0 36
G ua iaco l 0 .5 ) 6 -3 1 .5 3 0 /1 5 240
H y d ra s t in in e [0 .0 1 ) 6 -0 .0 6 0 .1 5 6 /1 5 48
Ipecac 0 .5 ) 6 -3 2 3 /2 180
Hyoscyamus 0 .2 ) 6 -1 ,2 0 .6 1 2 /6 240
Laudanum 0 .6 ) 6 -3 .6 6 3 6 /6 0 72
M e rc u r ic  I o d id e [0 .0 0 4 ) 6 -0 .0 2 4 0 .0 4 2 4 /4 0 72
Reproduced with permission o f the copyright owner. Further reproduction prohibited w ithout permission.
TABLE X H T  ( C o n tln u e d  )
40
C a lc u la te d Coder B a t io Kumber
P h a rm a c e u tic a ls A m e rica n Maximum d a i l y i n
d a i l y  dose f o r  24 h o u rs Maximum 1/1.20 _
M ercurous C h lo r id e (0 .1 2 ) 6 -0 .7 2 1 72 /100
M ercurous I o d id e ( 0 .0 1 ) 6 *0 V06 0 .2 6 /2 0 36
M orph ine ( 0 .0 1 ) 6 -0 ,0 6 0 .0 8 6 /8 90
M orph ine  H y d ro c h lo r id e (0 .0 0 8 ) 6 -0 .0 4 8 0 .0 8 4 8 /8 0 72
Opium (0 .0 6 ) 6 -0 .3 6 0 .6 3 6 /6 0 72
Ouabain (0 .0 0 0 2 5 ) 6 -0 .0 0 1 5  0 ,0 0 3 1 5 /3 0 60
P a p a ve rin e  H y d ro c h lo r id e ( 0 .1 ) 6—0 .6 0 .2 5 6 0 /2 5 288
P a ra ld ^ y d e U ) 6 -2 4 10 2 4 /1 0 288
H ie n y l S a l i c y la t e ( 0 .3 ) 6 - 1 .8 6 1 8 /6 0 36
P h é n o b a rb ita l ( 0 .0 3 ) 6 -0 .1 8 0 .5 1 8 /5 0
72P h ilo c a rp in e  H y d ro c h lo r id e (0 .0 0 5 ) 6 -0 .0 3 0 .0 5 3 /5
Ipecad and. Opium Powder i O .3 ) 6 - 1 .8 4 1 8 /4 0 54
S a n to n in 0 .0 6 ) 6 -0 .3 6 0 .3 3 6 /3 0 144
Scopo lam ine (0 ,0 0 0 5 ) 6 -0 .0 0 3 0 .0 0 3 3 /3 120
Sodium A rs e n a te (0 .0 0 3 ) 6 -0 .0 1 8 0 .0 2 1 8 /2 0 108
Sodium H y p o p h o s p h ite ( 0 .5 ) 6—3 0 .5 3 0 /5 720
Sodium C a c o d y la te ( 0 ,0 6 ) 6 -0 .3 6 0 .2 3 6 /2 0 216
A rs e n ic  and M e rc u r ic
6 /1 5Io d id e s  S o l* [ O . D 6 —0 .6 1 .5 48
S p a r te in e  S u l f a te 0 .0 3 ) 6 -0 .1 8 0 .3 1 8 /3 0 72
S try c h n in e 0 .0 0 1 5 ) 6 -0 ,0 0 9 0 .015 9 /1 5 72
A c o n ite  T in c tu r e 0 .6 ) 6—3 .6 1 .5 36 /15 288
B e lla d  ocna T in c tu r e 0 .6 ) 6 —3 .6 4 3 6 /4 0 108
Cantha r i d  i s  T in c tu r e [0 .1 ) 6—0 .6 1 .2 5 6 0 /1 2 5
C o lch lcum  T in c tu r e [2 ) 6 -1 2 6 1 2 /6 240
D ig i t a l i s  T in c tu r e [1 ) 6—6 6 6 /6 120
Io d in e  T in c tu r e 0 .3 ) 6—1 .8 3 1 8 /3 0 72
Hyoscyamus T in c tu r e 2 ) 6 -1 2 4 1 2 /4 360
L o b e lia  T in c tu r e [1 ) 6 -6 5 6 /5 144
Hux Vomica T in c tu r e (1 ) 6—6 5 6 /5 144
Opium T in c tu r e ( 0 .6 ) 6 -3 .6 6 3 6 /6 0 72
S tro p h a n tu s  T in c tu r e ( 0 .5 ) 6 -3 1 .5 3 0 ^ 5 240
Thymol ( 2 ) 6 -1 2 4 1 2 /4 360
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5 - 6 /5
4 -1 4- 9 /1 0  2 -1 /2  
2- 3 /4  I '  
1 -1 8 /2 ^  
1 5 -3 /5 1
; i
1 -1 2 /2 5  
3- 9 /2 0
2- 2 /5
1 -9 /2 5
5 -3 /1 0
1 -1 /1 0
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CCS^PAHISON CF ÀMEHICAK, FRENCH AND ENGUSH DOS33
French Am erican R a tio Number R a tio Number R a tio
Pha m a 0 eu t 1 oa Is Ih g l is h  E n g lis h  Maximum Average Minimum in Minimum in Maxima
Minimum Maximum one dose one dose codex 1 /120 U .S .P . 1 /120 Codex
A s p ir in Ù .3 TT™ ■” 1 .... 3 / iÛ "3'S— 3 /3 T 2 ( f~ “ 1/1
E p in e p h rin e 0.0001 0.0005 0.001 1 /1 0 12 5 /1 0
Ammonium D i lu te d 0 .6 1 .2 1 6 /1 0 72
1 /5
12/10
Apom orphine H y d ro o h lo r ld e 0.001 0.002 0.015 0.005 1/15 8 24 2/15 16
S i l v e r  N i t r a t e 0 .008 0.016 0 .0 3 8 /3 0 32 16/30 64
A rs e n ic  T r i  o r  id  e 0.001 0.005 0.005 1 /5 24
4 /5
5 /5 120
A rs e n ic  T r l io d id e 0 .004 0,016 0.005 0.005 4 /5 96 96 * 384A tro p in e 0.00025 0 .001 0.001 0.0004 25/100 30 25/40 75 120
B e l la donna 0 .0 3 0 .2 0 .15 3 /1 5 24 20/15 160
C a ffe in e 0 .1 2 0 .3 0 ,5 0 .2 12 /50 12 /20 72 3 /5 72
Carbon T e t ra c h lo r id e 2 4 2 .5 2 .5  ' 20 /25 96 20/25 96 40 /25 192
C h lo ra l H y d ra te 0 .3 1 .2 4 0 .6 3 /4 0 9 3 /6 60 12/40 36
C h lo ro fo rm 0.06 0 .3 0 .5 6 /5 0
8 /1 5
3 /5 72
C oca ine  end H y d ro c h lo r id e 0.008 0.016 0.05 0.015 8 /5 0 64 I 6/ 5O
C odeine and Phosphate 0.016 0.06 0 .1 0 .0 3 16/100 16/30 64 6 /10 72
C re o so te 0.12 0 .6 0 .5 0.25 12 /50 12/25 6 /5 144
Copper S u lfa te 0 .3 0 .6 0 .7 5 30 /25 48 60/75 96
D iam orph ine  H y d ro c h lo r id e 0,0025 0.008 0 .0 1 25/100 30
3 /1 0
8 /10 96
D ig i t a l i s 0 .0 3 0 .1 1 0 ,1 3 /1 0 36 36 1 /10 12
E phedrlne  H y d ro c h lo r id e 0.016 0 .1 0 .1 0.025 16/100 16 /25 1 /1 120
E rg o t 0 .3 1 1 3/10 36
15/15
1 /1 120
B e lladonna  E r t r a c t 0.015 0.06 0 .0 3 0.015 15 /30 60 120 6 /3 240























B tia rm aoautioa ls
F rench 
E n g lis h  E n g lis h  Maximum 
Minimum Maximum one dose






B a tio  
Minimum 
U .S .P .
Number l ^ t i o  
in  Maxlmui 
1 /120 Codex
E rgo t F lu id e x t r a c t 0 .5 1 .2 1 2 6 /1 0 72 6 /2 0 36 12/10
Ip e ca c  E x tra c t 0 .0 3 0 .12 0 .3 0 .5 3 /30 12 3 /50 12/30 48
Hyosoyamue E x tra c t 0.016 0.06 0 .1 0.05 16/100 I 6/ 5O 6 /10 72
Nux Vomica E x t in c t 0 .06 0 .2 0 .0 4 0 .015 6 /4 180 60 /15 480 20/4 600
Opium E x tra c t 0 .015 0.06 0 .1 0 .0 3 15/100 18 15 /30 60 6 /1 0 72
G ua laco l 0 .3 0 .6 0 .5 0 .5 3 /5 72 3 /5 72 6 /5 144
Io d o fo rm 0 .0 3 0 .2 0 .2 3/20 18 2 /2 120
Ip e c a c 1 2 2 0 .5 1 /2 60 10 /5 240 2 /2 120
laudanum 0 .3 2 2 0.6 3 /20 18 3 /6 60 2 /2 120
M e rc u r ic  C h lo r ld e 0.002 0 .004 0.015 2 /1 5 16 4 /15 52
M e rc u r ic  Io d id e 0.002 0 .004 0 .02 0,004 2 /2 0 12 2 /4 60 4 /2 0 24
M e rc u r ic  C h lo r id e 0 .0 3 0 .2 1 0 .12 3 /1 0 36 1/12 30 2 /10 24
B e ta n a p h to l 0 .3 0.6 1 3/10 36 6 /10 72
Nux Vomica 0.06 0 .25 0.1 6 /1 0 72 25/10 300
Opium 0 .03 0 .2 0 .2 0.06 3 /2 0 18 3 /6 60 2 /2 120
i^ ra ld e h y d e 2 8 5 4 2 /5 48 2 /4 60 8 /5 192
P heno l 0 .06 0 .2 0 .1 6 /1 0 72 2 /1 240
A n t ip y r in 0 .3 0 .6 2 3 /2 0 18 6 /20 36
P ilo c a r p in e 0 .003 0,012 0 .0 2 0.005 3/20 18 3 /5 72 12/20 72
P o ta ss iu m  C h lo ra te 0 .3 0 .6 1 3 /10 36 6 /1 0 72
U
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CONCLUSION
T w e n ty  p e r  c e n t  o f  th e  s ix t y - n in e  p h a rw a cou11c e  
o f f i c i a l  I n  t h e  U n ite d  S ta te s  P h a rm a co p e ia  X I I I  and th e  
R a t io n a l  F o rm u la ry  V I I Ï  f o l l o w  th e  r a t i o  t h r e e - t e n th s ,  and 
a b o u t f i f t y  p e r  c e n t  v a r y  be tw e e n  o n e - fo u r th  and o n e - h a l f  o f  
th e  Codex T I  maximum f o r  one d o s e , (T a b le  V * ) *  The same 
o b s e r v a t io n  may be made c o n c e rn in g  a l l  th e  U n ite d  S ta te s  
F h a rra a co p e la s  a v e ra g e  d o s e s , and th e  F re n c h  Codex V I m ax i­
mum d o s e s . Among 144  p h a rm a c e u t ic a ls ,  tw e lv e  p e r  c e n t  
f o l l o w  th e  r a t i o  t h r e e - t e n th s ,  f i f t y  p e r  c e n t  v a r y  be tw een 
o n e - f o u r t h  and o n e - h a l f ,  (T a b le  V I I ) .
G e n e r a l ly ,  U n ite d  S ta te s  P ha rm aco pe ia s  doses v a ry  
b e tw ee n  o n e - f o u r t h  and o n e - h a l f  o f  th e  Codex V I do ses  and , 
m ore a c c u r a te ly  th e  r a t i o  t h r e e - t e n th s  i s  th e  one w h ic h  
p e r s i s t s .  The o th e r  f i f t y  p e r  c e n t  o f  th e  p h a rm a c e u t ic a ls  
d e v ia t in g  fro m  th e  r u le  v a r y  I n  p r o p o r t io n  to  t h e i r  t o x i c i t y ,  
I n  th e  o r d e r  o f  th e  gram  d o s e s ,(T a b le  I X ) ,  among t h i r t y - o n e  
p h s c rn ia c e u tlc a lB , f i f t e e n  p e r  c a n t  f o l l o w  th e  r a t i o  th r e e -  
t e n th s ,  w h i le  a n o th e r  f i f t e e n  p e r  c e n t  g iv e  th e  r a t i o  two 
t o  one (d o u b le  o f  th e  C odex V I d o s e s ) .
I n  th e  o r d e r  o f  th e  d e c ig ra m  d o s e s , (T a b le  X I ) ,  
among f o r t y - f o u r  p h a rm a o a u t ic a le , a b o u t e le v e n  p e r  c e n t f o l ­
lo w  th e  r a t i o  t h r e e - t e n th s  w h i le  f o u r te e n  p e r  c e n t  a re  
B lm l la r  t o  th e  F re n c h  d o s e s .
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I n  th e  o r d e r  o f  th e  c e n t ig ra m  d o se s , ( T a b le  X I I I ) , 
among tw e n ty  p h n m A O e u t le n ls ,  t w e n t y - f i v e  p e r  c e n t  f o l l o w  
th e  m t l o  t h r e e - t e n  t h e , f i f t e e n  n e r  c e n t  c o rre c p o n d  t o  o n e - 
h a l f  o f  th e  F re n c h  d o s e s .
I n  th e  o r d e r  o f  th e  m i l l ig r a m  d o s e s , (T a b le  X Y ), 
among t h i r t e e n  p h a rm a c e u t ic a ls ,  o n ly  e ig h t  p e r  c e n t  f o l l o w  
th e  r a t i o  t h r e e - t e n t h s ,  w h i le  tw e n ty - th r e e  p e r  c e n t  a re  
s lm l l n r  t o  th e  F re n c h  d o s e s .
H ie  c u rv e  I n  F ig u r e  num ber 3 shows t h a t  th e  p e r ­
c e n ta g e  w i t h in  th e  r a t i o  t h r e e - t e n th s  v a r ie s  i n  in v e r s e  
p r o p o r t io n  w i t h  th e  t o x i c i t y  o f  th e  d ru g s ,  e x c e p t f o r  th e  
ôoeee o f  th e  c e n t ig ra m  I n  w h ic h  th e  p e rc e n ta g e  o f  r a t i o  
t h r e e -  t e n th s  i s  g re * - te r  th a n  a l l  th e  o th e rs  and I n  w h ic h  
th e  g r e a te s t  p e rc e n ta g e  o f  d ru g s  (s e v e n ty  p e r  c e n t)  v a r ie s  
b e tw een  o n e - f o u r t h  and one - h a l f  o f  th e  F re n ch  d o s e s . A ls o  
I t  I s  show n, (T a b le  X V ), t h a t  th e  g r e . - te s t  pourcentage o f  
A m e ric a n  d o se s  s im i l a r  to  th e  F re n c h  cnee le  fo u n d  i n  th e  
o r d e r  o f  th e  m i l l ig r a m .
The tw o  l i s t s  o f  A m e ric a n  maximum doses  g iv e n  by
<
th e  tw o  f o l l o w in g  n o n - o f f l o l a l  b o o ks  do n o t  g iv e  th e  same 
a n sw e r- ^
P h a rm a c e u t ic a l ' Ih e r a p o u t ic e *  shows t h ^ t  t h e i r  
A ve ra g e  d o re s  v a r y  b e tw e e n  th e  r a t i o s  t h r e s - t e n t h s  and
*  See, T a b le  X V I,  X V I I ,  > 7 / I I I -
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one-hall* of their maxliman doses in a ranr^o of two to ten, 
whiXe the PhaxTitaceutlcal Therapeutics Etaximum closes vary 
between, the unit and aix-flfths o f  the Codex V I r ia x lm im  in 
th e  same range o f  tw o  to ten. It is a kind o f  verification. 
The American mæ-clinum closes are nearly e q u iv a le n t  to the 
French maximum for one dose; th e  range of variation is simi­
lar when the American average doses are compai*ed to the 
American or French laaximums.
The results given by the United S ta te s  Dispensatory 
a re  different, (Table X I X ) ,  The average United States 
Tharmacopclas doses are Intermodlate to the Dispensatory 
m in im um  and maximum doses. The ratios ostablished between 
th e s e  two preceding doses still vary from tlipee-tenths to 
one-half, (Table XX) ; so those mxivaura doses are certainly 
inferior to tbo ones given by T] lanmc out leal Therapeutics,
I n  fact, they vary around t h r e e - f i f t h s  of the Codex VI 
maximum for one dose, (T a b le  ZOCI), Since the average United 
States Fhai-̂ iac0 1 3 0las doses are equivalent to tlirce-tenths 
of tiio Codex dose, it can bo stated that United States 
Pharmacopeias average doses a re  equal to one-half of the 
United Dtates Dispensatory maximum doses.
After a comparison of average and maximum American 
doses to the Codox VI maxlEiuzA for one dose, it is intr.rcsLing 
to compare the American daily doses to the Codex VI iua:s:i:.ran 
doses for twenty-four hours, (Table XXIII). As twenty per
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C e n t o f  th o a e  r a t i o s  rarj a ro u n d  t h r e e - f i f t h s ,  th e  f o l lo w in g  
c o n c lU B io n s  can be rsades
I n  a l l  th e  f o r e g o I n ;  o a lo u la t lo n e ,  th e  F rench  
Codex V I  maximum f o r  one tioee  h a s  been ta k e n  me a u n i t ,  
ï l i r e e  k in d s  o f  doses th e n  a p p e a rs
Codex V I  maximum f o r  one dome -  th e  u n i t
Ü . S . f . X I I X  a v e ra g e  dose -  S / lO  o f  th e  u n i t
A m e ric a n  dose f o r  24 h o u rs  -  3 /5  o f  th e  Codex V I
maximum f o r  P4 h o u rs .
The A iû e r lc a n  do ses  f o r  t '^ e n t y - f o u r  h o u rs  have been 
Calculated as s i x  t im e s  th e  a v e ra g e  U n ite d  S ta te s  P harm acope ias  
doses  and c o r re s p o n d  t o  e ig h t © en -te n th s  o f  th e  u n i t .  T ha t 
makes th e  Codex V I maximum f o r  tw e n t y - fo u r  h o u rs  th re e  t im e s  
g r e a t e r  th a n  th e  Codex V I  maximum f o r  one dose* I t  has been 
e s ta b l is h e d  t h a t :
Codex V I maximum f o r  one dose  -  1 /3  o f  Codex V I maximum
f o r  24 h o u rs
U .S .P . X I I I  a v e ra g e  dose  -• 3 /1 0  o f  Codex V I maximum
f o r  one dose , o r  
l / l O  o f  Codex v% p-aximum 
f o r  24 h o u rs .
To d e c id e  w h ic h  I s  th e  m ost u s e fu l  o f  a l l  th o s e  d o s e s , 
th e  s tu d y  o f  a t h i r d  p h a rm a c o p e ia  I s  I n t e r e s t i n g . *
The m inim um  and maximum E n g l is h  doses h a re  been 
s tu d ie d  and hove  shown t h a t  th e . m inimum E n g l1 ah doses v a ry  
a ro u n d  th e  r a t i o  t h r e e - t w e n t le t h a  o f  th e  F re n c h  maximum f o r  
one d o ^e  and o n e - h a l f  o f  th e  a v e ra g e  U n ite d  c ta ta s
•  See, T a b le s  X X IV , XXV, X X V I, X X V II .
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Phf»rD*acopelftp domes, w h i le  th e  mRTlmunj £ n . ; l ip h  domes 
c o r re s p o n d  to  th e  r a t i o  t h r e e - f l f t h e  o f  th e  F re n c h  
f o r  one dome. S in c e  th e  U n ite d  B ta te e  U isp*^npA ,tory f f ia r l -  
mua domes a re  a ls o  i n  th e  m t l o  t h r e e - f i f t h s  o f  th e  F rench  
maximum f o r  one d o s e , i t  ham been e m ta b lim h e d  t h a t  th e  
E n g l is h  M inim um  dome e o u a ls  one h a l f  o f  th e  U n ite d  Stmtem 
P h a rm a co p e ia s  a v e ra g e  dose  and t h a t  th e  fe in g lish  mnrlmum 
d o ses  a re  s i m i l a r  t o  th e  U n ite d  S ta to n  D in p e n e a to ry  domes.
SUkkARX
From a l l  th e s e  c a lc u la t io n s ,  th e  r a t i o  th r e e -  
te n th s  a p p e a rs  to  be  th e  b e s t  com parim on be tw een  A m erican  
and F re n c h  o f f i c i a l  doeem*
V d ii le  th e  U n ite d  S ta te s  P harm acope ia  i s  in te r e s t e d  
i n  a v e ra g e  d o se s  and th e  F re n c h  Codex i n  maximum domes o n ly ,  
th e  i i n g l i s h  P h a rm a co p e ia  makes b o th  o f  them o f f i c i a l ,  b u t  
keeps  i t s  s ta n d a rd  a  l i t t l e  c lo s e r  to  th e  Am erlcm n one .
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